Virpax Pharmaceuticals (VRPX) S-1 9 Sep 21 IPO registration Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	Virpax Pharmaceuticals, Inc.
Document Type	S-1
Amendment Flag	false
Entity Central Index Key	0001708331
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Incorporation, State or Country Code	DE

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020	[1]	Dec. 31, 2019
Current assets
Cash	$ 10,466,774	$ 54,796		$ 41,536
Prepaid expenses and other current assets	920,922	18,273		5,183
Total current assets	11,387,696	73,069		46,719
Deferred financing costs		392,337
Total assets	11,387,696	465,406		46,719
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Accounts payable and accrued expenses	2,779,866	3,115,924		1,514,474
Notes payable	50,510	543,990		264,520
Related party notes payable				1,000,000
Total current liabilities	2,830,376	3,659,914		2,778,994
Notes payable, net of current portion	21,590	21,590
Related party notes payable	1,000,000	1,000,000
Related party notes payable, net of current portion
Total long-term liabilities	1,021,590	1,021,590
Total liabilities	3,851,966	4,681,504		2,778,994
Commitments and contingencies
Preferred stock
Common stock	50	31		30
Additional paid-in capital	22,906,214	6,431,715		3,575,886
Accumulated deficit	(15,370,534)	(10,647,844)		(6,308,191)
Total stockholders’ equity (deficit)	7,535,730	(4,216,098)		(2,732,275)
Total liabilities and stockholders’ equity (deficit)	$ 11,387,696	$ 465,406		$ 46,719
[1]	Derived from audited financial statements

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.00001	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	10,000,000	10,000,000	1,000,000
Preferred stock, shares issued			0
Preferred stock, shares outstanding			0
Common stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000	20,000,000
Common stock, shares issued	4,960,153	3,145,153	3,018,673
Common stock, shares outstanding	4,960,153	3,145,153	3,018,673

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
OPERATING EXPENSES
General and administrative	$ 1,988,972	$ 1,061,850	$ 3,262,544	$ 1,510,835	$ 2,904,104	$ 2,559,127
Research and development	316,565	168,673	1,391,565	335,553	1,291,615	622,741
Total operating expenses	2,305,537	1,230,523	4,654,109	1,846,388	4,195,719	3,181,868
Loss from operations	(2,305,537)	(1,230,523)	(4,654,109)	(1,846,388)	(4,195,719)	(3,181,868)
OTHER (EXPENSE) INCOME
Interest expense	(34,049)	(43,261)	(64,748)	(83,891)	(147,934)	(124,644)
Other income (expense), net	(3,833)	4,000	(3,833)	4,000	4,000
Total other income					(143,934)	(124,644)
Loss before tax provision	(2,343,419)	(1,269,784)	(4,722,690)	(1,926,279)	(4,339,653)	(3,306,512)
Benefit from income taxes
Net loss	$ (2,343,419)	$ (1,269,784)	$ (4,722,690)	$ (1,926,279)	$ (4,339,653)	$ (3,306,512)
Basic and diluted net loss per share (in Dollars per share)	$ (0.47)	$ (0.41)	$ (1.06)	$ (0.63)	$ (1.40)	$ (1.13)
Basic and diluted weighted average common stock outstanding (in Shares)	4,958,999	3,086,384	4,454,877	3,065,636	3,107,502	2,929,005

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited) - USD ($)	Preferred stock	Common stock	Additional paid-in capital	Accumulated deficit	Total
Balance at Dec. 31, 2018		$ 29	$ 1,808,926	$ (3,001,679)	$ (1,192,724)
Balance (in Shares) at Dec. 31, 2018		2,874,437
Common stock issued pursuant to subscription agreements		$ 1	624,999		625,000
Common stock issued pursuant to subscription agreements (in Shares)		63,203
Common stock issued in payment of consulting services and settlement of accounts payable			463,815		463,815
Common stock issued in payment of consulting services and settlement of accounts payable (in Shares)		46,903
Stock-based compensation			678,146		678,146
Restricted stock awards granted
Restricted stock awards granted (in Shares)		34,130
Net loss				(3,306,512)	(3,306,512)
Balance at Dec. 31, 2019		$ 30	3,575,886	(6,308,191)	(2,732,275)
Balance (in Shares) at Dec. 31, 2019		3,018,673
Common stock issued pursuant to subscription agreements			425,000		425,000
Common stock issued pursuant to subscription agreements (in Shares)		42,978
Common stock issued in payment of consulting services and settlement of accounts payable			1,781		1,781
Common stock issued in payment of consulting services and settlement of accounts payable (in Shares)		180
Stock-based compensation			130,990		130,990
Restricted stock awards granted
Restricted stock awards granted (in Shares)		3,792
Net loss				(656,495)	(656,495)
Balance at Mar. 31, 2020		$ 30	4,133,657	(6,964,686)	(2,830,999)
Balance (in Shares) at Mar. 31, 2020		3,065,623
Balance at Dec. 31, 2019		$ 30	3,575,886	(6,308,191)	(2,732,275)
Balance (in Shares) at Dec. 31, 2019		3,018,673
Common stock issued pursuant to subscription agreements		$ 1	1,376,899		1,376,900
Common stock issued pursuant to subscription agreements (in Shares)		139,220
Common stock issued in payment of consulting services and settlement of accounts payable			5,288		5,288
Common stock issued in payment of consulting services and settlement of accounts payable (in Shares)		533
Stock-based compensation			1,473,642		1,473,642
Restricted stock awards granted
Restricted stock awards granted (in Shares)		6,952
Restricted stock awards forfeited
Restricted stock awards forfeited (in Shares)		(20,225)
Net loss				(4,339,653)	(4,339,653)
Balance at Dec. 31, 2020		$ 31	6,431,715	(10,647,844)	(4,216,098)	[1]
Balance (in Shares) at Dec. 31, 2020		3,145,153
Balance at Mar. 31, 2020		$ 30	4,133,657	(6,964,686)	(2,830,999)
Balance (in Shares) at Mar. 31, 2020		3,065,623
Common stock issued pursuant to subscription agreements		$ 1	843,899		843,900
Common stock issued pursuant to subscription agreements (in Shares)		85,325
Common stock issued in payment of consulting services and settlement of accounts payable			1,125		1,125
Common stock issued in payment of consulting services and settlement of accounts payable (in Shares)		113
Stock-based compensation			571,691		571,691
Restricted stock awards granted
Restricted stock awards granted (in Shares)		3,160
Restricted stock awards forfeited
Restricted stock awards forfeited (in Shares)		(20,225)
Net loss				(1,269,784)	(1,269,784)
Balance at Jun. 30, 2020		$ 31	5,550,372	(8,234,470)	(2,684,067)
Balance (in Shares) at Jun. 30, 2020		3,133,996
Balance at Dec. 31, 2020		$ 31	6,431,715	(10,647,844)	(4,216,098)	[1]
Balance (in Shares) at Dec. 31, 2020		3,145,153
Common stock issued pursuant to initial public offering, net of offering costs of $2,216,793		$ 18	15,783,189		15,783,207
Common stock issued pursuant to initial public offering, net of offering costs of $2,216,793 (in Shares)		1,800,000
Stock-based compensation			369,884		369,884
Net loss				(2,379,271)	(2,379,271)
Balance at Mar. 31, 2021		$ 49	22,584,788	(13,027,115)	9,557,722
Balance (in Shares) at Mar. 31, 2021		4,945,153
Stock-based compensation			321,427		321,427
Restricted stock awards granted		$ 1	(1)
Restricted stock awards granted (in Shares)		15,000
Net loss				(2,343,419)	(2,343,419)
Balance at Jun. 30, 2021		$ 50	$ 22,906,214	$ (15,370,534)	$ 7,535,730
Balance (in Shares) at Jun. 30, 2021		4,960,153
[1]	Derived from audited financial statements

Condensed Statements of Chang_2

Condensed Statements of Changes in Stockholders’ Equity (Deficit) (Unaudited) (Parentheticals)	3 Months Ended
	Mar. 31, 2021USD ($)
Statement of Stockholders' Equity [Abstract]
Offering costs	$ 2,216,793

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,722,690)	$ (1,926,279)	$ (4,339,653)	$ (3,306,512)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash interest expense	64,748	83,891	147,934	124,644
Stock-based compensation	691,311	702,681	1,473,642	678,146
Common stock issued in payment of consulting services and settlement of accounts payable		2,906	5,288	439,999
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(902,649)	346,940	(13,090)	7,947
Deferred financing costs		(73,000)
Subscription receivable		(375,000)
Accounts payable and accrued expenses	(8,469)	647,234	1,341,019	923,942
Net cash used in operating activities	(4,877,749)	(590,627)	(1,384,860)	(1,131,834)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of notes payable	(493,480)
Proceeds from the issuance of debt		72,100	72,100	500,000
Proceeds from related party notes payable	100,000
Repayment of related party notes payable	(100,000)
Deferred financing costs			(50,880)
Proceeds from the issuance of stock		893,900	1,376,900	625,000
Offering costs related to initial public offering	(2,216,793)
Proceeds from initial public offering of common stock	18,000,000
Net cash provided by financing activities	15,289,727	966,000	1,398,120	1,125,000
Net change in cash	10,411,978	375,373	13,260	(6,834)
Cash, beginning of period	54,796	41,536	41,536	48,370
Cash, end of period	10,466,774	416,909	54,796	41,536
Supplemental disclosure of cash and non-cash financing activities
Cash paid for interest	34,707
Cash paid for taxes
Debt issued in payment of consulting services and settlement of accounts payable		$ 169,740	228,960	264,520
Common stock issued in payment of consulting services and settlement of accounts payable				23,816
Deferred financing costs, included in accounts payable and accrued expenses			$ 341,457

Business and Liquidity

Business and Liquidity	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Business and Liquidity [Abstract]
Business and Liquidity	Note 1. Business and Liquidity Business Virpax Pharmaceuticals, Inc. (“Virpax” or the “Company”) was incorporated on May 12, 2017 in the state of Delaware. Virpax is a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems. Virpax has exclusive global rights to a proprietary patented Topical Spray Film Delivery Technology for acute musculoskeletal pain (“Epoladerm”). Virpax also has exclusive global rights to a proprietary patented injectable “local anesthetic” Liposomal Gel Technology for postoperative pain management (“Probudur”). Additionally, Virpax has exclusive global rights to a proprietary patented Nanomerics’ Molecular Envelope Technology (“MET”) that uses an intranasal device to deliver enkephalin for the management of acute and chronic pain, including pain associated with cancer (“NES100”). NES100 would support the current effort among prescribers, regulators, and patients to seek non-opioid and non-addictive treatment options to combat the opioid epidemic. Virpax will utilize these delivery technologies to selectively develop a portfolio of patented 505(b)(2) and new chemical entity (“NCE”) candidates for commercialization. While the Company is currently focused on the development of its non-opioid and non-addictive pain management pipeline of product candidates, the Company also plans on using its proprietary delivery technologies to develop anti-viral therapies (“MMS019”) as an anti-viral barrier to potentially prevent or reduce the risk or the intensity of viral infections in humans, including, but not limited to, influenza and SARS-CoV-2 (COVID 19). The Company, since inception, has been engaged in organizational activities, including raising capital and research and development activities. The Company has not generated revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flow from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any preclinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital. The Company incurred a net loss of $4,722,690 and $1,926,279 for the six months ended June 30, 2021 and 2020, respectively, and had an accumulated deficit of $15,370,534 as of June 30, 2021. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of debt and equity securities. On February 16, 2021, the Company announced the pricing of its initial public offering (the “IPO”) of 1,800,000 shares of its common stock at an initial offering price of $10.00 per share. The Company’s common stock commenced trading on the NASDAQ on February 17, 2021 under the ticker symbol “VRPX”. The IPO closed on February 19, 2021. The gross proceeds from the IPO were $18.0 million. The net proceeds of the IPO were approximately $15.8 million after deducting underwriting discounts, commissions and offering expenses payable by the Company, including offering costs paid and offering costs accrued and unpaid as of December 31, 2020. In conjunction with the IPO, the Company granted the underwriters warrants to purchase 90,000 shares of Company common stock at an exercise price of $12.50 per share, which was 125% of the initial public offering price. In addition, with respect to the ongoing and evolving coronavirus (“COVID-19”) outbreak, which was designated as a pandemic by the World Health Organization on March 11, 2020, the outbreak has caused substantial disruption in international and U.S. economies and markets and if repercussions of the outbreak are prolonged, could have a significant adverse impact on the Company’s business. Management believes that current cash is sufficient to fund operations and capital requirements through the third quarter 2022. Additional financings will be needed by the Company to fund its operations, to complete clinical development of and to commercially develop its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms. The Company also has the ability to curtail spending in research and development activities in order to conserve cash.	Note 1. Business and Liquidity Business Virpax Pharmaceuticals, Inc. (“Virpax” or “Company”) was incorporated on May 12, 2017 in the state of Delaware. Virpax is a company specializing in developing pharmaceutical products for pain management by using new drug delivery systems. Virpax has exclusive global rights to a proprietary patented Topical Spray Film Delivery Technology for acute musculoskeletal pain (“Epoladerm”). Virpax also has exclusive global rights to a proprietary patented injectable “local anesthetic” Liposomal Gel Technology for postoperative pain management (“Probudur”). Additionally, Virpax has exclusive global rights to a proprietary patented Nanomerics’ Molecular Envelope Technology (“MET”) that uses an intranasal device to deliver enkephalin for the management of acute and chronic pain, including pain associated with cancer (“NES100”). NES100 would support the current effort among prescribers, regulators, and patients to seek non-opioid and non-addictive treatment options to combat the opioid epidemic. Virpax will utilize these delivery technologies to selectively develop a portfolio of patented 505(b)(2) and new chemical entity (“NCE”) candidates for commercialization. Liquidity and Going Concern The Company, since inception, has been engaged in organizational activities, including raising capital and research and development activities. The Company has not generated revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flow from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any preclinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital. The Company incurred a net loss of $4,339,653 and $3,306,512 for the years ended December 31, 2020 and 2019, respectively, and had an accumulated deficit of $10,647,844 as of December 31, 2020. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of debt and equity securities. The Company closed its initial public offering in February 2021 raising net proceeds of approximately $16,000,000 from the issuance of 1,800,000 shares of its common stock. In addition, with respect to the ongoing and evolving coronavirus (“COVID-19”) outbreak, which was designated as a pandemic by the World Health Organization on March 11, 2020, the outbreak has caused substantial disruption in international and U.S. economies and markets and if repercussions of the outbreak are prolonged, could have a significant adverse impact on the Company’s business. Management believes that current cash is sufficient to fund operations and capital requirements through approximately November 2022. Additional financings will be needed by the Company to fund its operations, to complete clinical development of and to commercially develop its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation Use of Estimates Significant items subject to such estimates and assumptions include research and development accruals and the valuation of stock-based compensation. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes. Basic and Diluted Loss per Share Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 Six Months Six Months Equivalent common shares Stock options 736,593 486,101 736,593 486,101 Warrants 95,056 — 95,056 — RRD note conversion — 43,909 — 43,909 Cash Fair Value of Financial Instruments Research and Development Stock-based Compensation Determining the appropriate fair value of share-based awards requires the use of subjective assumptions, including the fair value of the Company’s common shares, and for options, the expected life of the option and expected share price volatility. The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represents management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. The expected life of options was estimated using the simplified method, as the Company has historical information to develop reasonable expectations about future exercise patterns and post-vesting employment. Income Taxes The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of June 30, 2021, the Company had no uncertain income tax positions.	Note 2. Summary of Significant Accounting Policies Basis of Presentation Use of Estimates Significant items subject to such estimates and assumptions include research and development accruals and the valuation of stock-based compensation. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes. Basic and Diluted Loss per Share Year Ended Year Ended Equivalent common shares Stock options 486,101 236,458 Warrants 5,056 — RRD note conversion 49,897 26,746 Cash Fair Value of Financial Instruments Research and Development Stock-based Compensation Determining the appropriate fair value of share-based awards requires the use of subjective assumptions, including the fair value of the Company’s common shares, and for options, the excepted life of the option and expected share price volatility. The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represents management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. The expected life of options was estimated using the simplified method, as the Company has historical information to develop reasonable expectations about future exercise patterns and post-vesting employment. Income Taxes The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of December 31, 2020, the Company had no uncertain income tax positions.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2020
Prepaid Expenses And Other Current Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	Note 3. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consists of the following: December 31, December 31, Prepaid insurance $ 8,257 $ 3,328 Legal retainer 3,643 — Consulting fees 5,838 — Accounts receivable, related party - 1,388 Other prepaid expenses and current assets 534 1,855 $ 18,273 $ 5,183

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	Note 4. Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consists of the following: June 30, December 31, Deferred CEO compensation $ 1,073,075 $ 1,028,110 Research and development expenses 69,605 1,045,503 Insurance premiums 448,789 2,874 Legal expenses 768,811 437,471 Professional fees 47,748 253,462 Interest payable/accrued 291,406 270,000 Accounting consulting fees 6,235 45,904 Tax expenses 10,000 13,365 Other 64,197 19,235 $ 2,779,866 $ 3,115,924	Note 4. Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities consists of the following: December 31, December 31, Deferred CEO compensation $ 1,028,110 $ 680,400 Research and development expenses 1,045,505 275,429 Legal expenses 437,471 200,062 Professional fees 253,462 177,096 Interest payable/accrued 270,000 138,762 Accounting consulting fees 45,904 24,765 Taxes 13,365 14,465 Other 22,107 3,495 $ 3,115,924 $ 1,514,474

Notes Payable

Notes Payable	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes Payable	Note 5. Notes Payable On October 1, 2018, the Company entered into a promissory note (the “2018 Promissory Note”), which promises to pay Anthony Mack, Chief Executive Officer and significant investor, the principal amount of $500,000, and bears interest at a rate of 11.19% per annum. The 2018 Promissory Note states that the principal shall be paid at the earlier of an event of default (as defined in the 2018 Promissory Note) and the first anniversary of the date of the 2018 Promissory Note. As of June 30, 2021, the balance on the 2018 Promissory note was $500,000, with accrued interest of $153,862. As of December 31, 2020, the balance on the 2018 Promissory Note was $500,000, with accrued interest of $125,887. On January 15, 2019, the Company entered into a promissory note (the “2019 Promissory Note”), which promises to pay Anthony Mack the principal amount of $500,000, and bears interest at a rate of 11.19% per annum. The 2019 Promissory Note states that the principal shall be paid at the earlier of an event of default (as defined in the 2019 Promissory Note) and the first anniversary of the date of the 2019 Promissory Note. On April 6, 2020, the Company and Anthony Mack entered into an amendment to the 2019 Promissory Note which extended the maturity date from the first anniversary of the date of the 2019 Promissory Note to January 15, 2021, with all other terms remaining consistent. As of June 30, 2021, the balance on the 2019 Promissory Note was $500,000, with accrued interest of $137,544. As of December 31, 2020, the balance on the 2019 Promissory Note was $500,000, with accrued interest of $109,569. On October 28, 2020, the Company amended its 2018 Promissory Note and its 2019 Promissory Note with Anthony Mack to extend the maturity date to December 31, 2023 for both promissory notes. All other terms and conditions of these promissory notes remained unchanged. In January 2021, the Company issued notes with an aggregate principal amount of $75,000 and $25,000, respectively. These notes were issued to Anthony Mack for $75,000 and Christopher Chipman, Chief Financial Officer, for $25,000. These notes bore interest as a rate of 1.35% per annum and were subsequently repaid with proceeds from the IPO, including accrued interest of $122 and $41, respectively. On August 29, 2019, the Company entered into a service provider convertible note purchase agreement (the “RRD Note”) with RRD International, LLC (“RRD”). Under the RRD Note, the Company and RRD agreed to make certain compensation due to RRD payable in the form of a convertible promissory note. The RRD Note stated that a maximum principal balance of $400,000 could be applied for services provided by RRD to the Company, which could be converted into equity or cash (all or in part) upon a Qualified Financing (as defined in the RRD Note) or the Conversion Date of March 31, 2020. Borrowings under the RRD Note bore simple interest on the outstanding principal amount of the RRD Note until paid in full at the fixed rate of 10% per annum. During 2020, the RRD Note was amended to increase the maximum principal to $600,000 and to extend the maturity and conversion dates through to January 31, 2021. As of December 31, 2020, the balance on the RRD Note was $493,480, with accrued interest of $34,544. In February 2021, the Company paid the balance on its RRD Note of $528,024, including $34,544 of accrued interest, with proceeds from the Company’s IPO. On May 4, 2020, the Company entered into a Promissory Note (the “PPP Note”) with PNC Bank as the lender (the “Lender”), pursuant to which the Lender agreed to make a loan to the Company under the Paycheck Protection Program (the “PPP Loan”) offered by the U.S. Small Business Administration (the “SBA”) in a principal amount of $72,100 pursuant to Title 1 of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”). The PPP Loan proceeds are available to be used to pay for payroll costs, including salaries, commissions, and similar compensation, group health care benefits, and paid leaves; rent; utilities; and interest on certain other outstanding debt. The amount that will be forgiven will be calculated in part with reference to the Company’s full time headcount during the period ending October 31, 2020. The interest rate on the PPP Note is a fixed rate of 1% per annum. To the extent that the amounts owed under the PPP Loan, or a portion of them, are not forgiven, the note shall convert to an amortizing term loan and the Company will be required to make principal and interest payments in monthly installments beginning seven months from April 2020. The PPP Note matures in two years. The PPP Note includes events of default. Upon the occurrence of an event of default, the Lender will have the right to exercise remedies against us, including the right to require immediate payment of all amounts due under the PPP Note. On July 2, 2021, the SBA notified the Company that the forgiveness amount totaled $61,816. The remaining balance of $10,284 must be repaid by the Company on or before maturity. The following table summarizes the Company’s notes payables: June 30, 2021 Balance as of Notes Issued Note Balance as of Related party notes payable Anthony Mack 2018 Promissory Note $ 500,000 $ — $ — $ 500,000 Anthony Mack 2019 Promissory Note 500,000 — — 500,000 Related party notes payable — 100,000 (100,000 ) — Total related party notes payable 1,000,000 100,000 (100,000 ) 1,000,000 RRD Note 493,480 — (493,480 ) — SBA PPP Loan 72,100 — — 72,100 Total notes payable 1,565,580 100,000 (593,480 ) 1,072,100 Less: Current portion of notes payable 543,990 100,000 (593,480 ) 50,510 Total non-current portion of notes payable $ 1,021,590 $ — $ — $ 1,021,590 Interest expense was $64,748 and $83,891 for the six months ended June 30, 2021 and 2020, respectively. Interest expense was $34,049 and $43,261 for the three months ended June 30, 2021 and 2020, respectively. Principal payments on note payables are due as follows: Years ending December 31, 2021 $ 50,510 2022 21,590 2023 1,000,000 Total payments $ 1,072,100	Note 5. Notes Payable On October 1, 2018, the Company entered into a promissory note (the “2018 Promissory Note”), which promises to pay Anthony Mack, Chief Executive Officer and significant investor, the principal amount of $500,000, and bear interest at a rate of 11.19% per annum. The 2018 Promissory Note states that the principal shall be paid at the earlier of an event of default and the first anniversary of the date of the note. As of December 31, 2020, the balance on the 2018 Promissory Note was $500,000, with accrued interest of $125,887. As of December 31, 2019, the balance on the 2018 Promissory note was $500,000, with accrued interest of $74,692. On January 15, 2019, the Company entered into a promissory note (the “2019 Promissory Note”), which promises to pay Anthony Mack the principal amount of $500,000, and bear interest at a rate of 11.19% per annum. The 2019 Promissory Note states that the principal shall be paid at the earlier of an event of default and the first anniversary of the date of the note. On April 6, 2020, VIRPAX and Anthony Mack entered into an amendment to the 2019 Promissory Note which extended the maturity date from the first anniversary of the date of the 2019 Promissory Note to January 15, 2021 with all other terms remaining consistent. As of December 31, 2020, the balance on the 2019 Promissory Note was $500,000, with accrued interest of $109,569. As of December 31, 2019, the balance on the 2019 Promissory Note was $500,000, with accrued interest of $56,329. On October 28, 2020, the Company amended its 2018 Promissory Note dated October 1, 2018 and its 2019 Promissory Note dated January 15, 2019 with Anthony Mack, Chief Executive Officer and significant investor, to extend the maturity date to December 31, 2023 for both promissory notes. All other terms and conditions of these promissory notes remained unchanged. On August 29, 2019, the Company entered into a service provider convertible note purchase agreement (the “RRD Note”) with RRD International, LLC (“RRD”). Under this agreement, Virpax and RRD agreed to make certain compensation payable in the form of a convertible promissory note. The convertible promissory note states that a maximum principal balance of $400,000 can be applied for services provided by RRD to Virpax, which can be converted into equity or cash (all or in part) upon a Qualified Financing or the Conversion Date of March 31, 2020. Borrowings under the RRD Note bear simple interest on the outstanding principal amount of the RRD Note until paid in full at the fixed rate of 10% per annum. On March 20, 2020, VIRPAX and RRD entered into an amendment which extended the maturity date from March 31, 2020 to September 30, 2020, increased the amount of principal from $400,000 to $600,000, extended the Qualified Financing deadline from March 31, 2020 to September 30, 2020, and provided for the payment of all interest accrued up to March 31, 2020 which totaled $16,435. As of December 31, 2020, the balance on the RRD Note was $493,480, with accrued interest of $34,544. As of December 31, 2019, the balance on the RRD Note was $264,520, with accrued interest of $7,741. In October 2020, the Company amended the RRD Note to extend the maturity date from September 30, 2020 to November 30, 2020, and to extend the RRD Qualified Financing deadline from September 30, 2020 to November 30, 2020, and provide for the payment of all interest accrued from April 1, 2020 through November 30, 2020, which was $30,431. On November 30, 2020, the Company amended the RRD Note to extend the conversion date to December 31, 2020. On December 31, 2020, we amended the RRD Note to extend the conversion date to January 31, 2021 (See also Note 12 – Subsequent Events On May 4, 2020, the Company entered into a Promissory Note (the “PPP Note”) with PNC Bank as the lender (the “Lender”), pursuant to which the Lender agreed to make a loan to us under the Paycheck Protection Program (the “PPP Loan”) offered by the U.S. Small Business Administration (the “SBA”) in a principal amount of $72,100 pursuant to Title 1 of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”). The PPP Loan proceeds are available to be used to pay for payroll costs, including salaries, commissions, and similar compensation, group health care benefits, and paid leaves; rent; utilities; and interest on certain other outstanding debt. The amount that will be forgiven will be calculated in part with reference to the Company’s full time headcount during the period ending October 31, 2020. The interest rate on the PPP Note is a fixed rate of 1% per annum. To the extent that the amounts owed under the PPP Loan, or a portion of them, are not forgiven, the note shall convert to an amortizing term loan and the Company will be required to make principal and interest payments in monthly installments beginning seven months from April 2020. The PPP Note matures in two years. The PPP Note includes events of default. Upon the occurrence of an event of default, the Lender will have the right to exercise remedies against us, including the right to require immediate payment of all amounts due under the PPP Note. The following table summarizes the Company’s notes payables: December 31, 2020 Balance as of Notes Balance as of Related party notes payable Anthony Mack 2018 Promissory Note $ 500,000 $ — $ 500,000 Anthony Mack 2019 Promissory Note 500,000 — 500,000 Total related party notes payable 1,000,000 — 1,000,000 RRD Note 264,520 228,960 493,480 SBA PPP Loan — 72,100 72,100 Total notes payable $ 1,264,520 $ 301,060 $ 1,565,580 Less: Current portion of notes payable 1,264,520 279,470 543,990 Total non-current portion of notes payable $ — $ 21,590 $ 1,021,590 December 31, 2019 Balance as of Notes Balance as of Related party notes payable Anthony Mack 2018 Promissory Note $ 500,000 $ — $ 500,000 Anthony Mack 2019 Promissory Note — 500,000 500,000 Total related party notes payable 500,000 500,000 1,000,000 RRD Note — 264,520 264,520 Total notes payable 500,000 764,520 1,264,520 Less: Current portion of notes payable 500,000 764,520 1,264,520 Total non-current portion of notes payable $ — $ — $ — Interest expense was $147,934 and $124,644 for the year ended December 31, 2020 and 2019, respectively. Principal payments on note payables are due as follows: Years ending December 31, 2021 $ 543,990 2022 21,590 2023 1,000,000 2024 — Total payments $ 1,565,580

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6. Commitments and Contingencies Employment Agreements The Company has an employment agreement with Anthony Mack, the Company’s Chief Executive Officer (“CEO”), effective September 18, 2018. The agreement may be terminated by either party at any time upon written notice provided to the other party. Concurrent with the employment agreement, the CEO and the Company agreed to an Executive Confidentiality Agreement that contains standard non-closure and non-competition provisions. In the event we terminate the employment agreement other than for cause, or the CEO terminates the agreement for good reason, we will pay the CEO the then effective base salary for a period of twelve months following the effective date of the termination. However, payment of the effective base salary is subject to the execution of a release form and the compliance by the CEO with the release and all terms and provisions of the employment agreement and Executive Confidentiality Agreement that survive the termination of employment. The Company’s Chief Executive Officer also elected to defer salary temporarily. Deferred compensation due to the Company’s Chief Executive Officer amounted to $1,052,000 and $1,005,000 as of June 30, 2021 and December 31, 2020, respectively, which is included in accounts payable and accrued expenses on the accompanying condensed balance sheets. In March 2021, the Company’s Chief Executive Officer ceased deferring compensation. Litigation From time to time the Company is subject to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows. On March 12, 2021, the Company and Mr. Mack (the “defendants”) were named as defendants in a complaint (the “Complaint”) filed by Sorrento Therapeutics, Inc. (“Sorrento”) and Scilex Pharmaceuticals Inc. (“Scilex” and together with Sorrento, the “Plaintiffs”) in the Court of Chancery of the State of Delaware. In the Complaint the Plaintiffs allege (i) Mr. Mack breached a Restrictive Covenants Agreement, dated as of November 8, 2016, between himself and Sorrento (the “Restrictive Covenants Agreement”), (ii) the Company tortiously interfered with the Restrictive Covenants Agreement, and (iii) the Company tortiously interfered with Scilex’s relationship with Mr. Mack. On May 7, 2021 Plaintiffs filed an Amended Complaint (the “Amended Complaint”) asserting the same three causes of action. Simultaneously with filing the original Complaint, the Plaintiffs filed a motion to expedite, seeking a hearing in four weeks on their prospective motion for a preliminary injunction, prohibiting Mr. Mack’s alleged violations of the Restrictive Covenants Agreement and prohibiting the alleged tortious interference. On March 22, 2021, Vice Chancellor Paul A. Fioravanti Jr. issued a scheduling order, setting forth terms which had been agreed to by the parties, under which oral argument on Plaintiffs’ proposed motion for preliminary injunction was scheduled for July 15, 2021. On May 17, 2021, Mr. Mack and the Company filed a motion to dismiss the Amended Complaint. On May 18, 2021, the Vice Chancellor issued a revised scheduling order, also setting forth terms which had been agreed to by the parties, under which a briefing schedule was set with respect to Defendants’ motion to dismiss, Plaintiffs agreed not to move for a preliminary injunction, and a trial in the action was set for February 9-11, 2022. As of July 12, 2021, the parties completed briefing on the motion to dismiss the Amended Complaint. The Court has not yet scheduled a date for oral argument on the motion to dismiss. The Company believes that the allegations in the Amended Complaint are wholly without merit, and the Company intends to vigorously defend the action. However, the Company is unable to predict the ultimate outcome of the lawsuit at this time. Global Pandemic Outbreak In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (“COVID-19”) a global pandemic. The outbreak has become increasingly widespread in the United States, impacting the markets in which the Company operates. While the full impact of the pandemic continues to evolve, the financial markets have been subject to significant volatility that adversely impacts the Company’s ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing initiatives. The uncertain financial markets, disruptions in supply chains, mobility restraints, and changing priorities as well as volatile asset values also affect the Company’s ability to enter into collaborations, joint ventures, and license and royalty agreements. The outbreak and government measures taken in response to the pandemic have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, have spiked, while demand for other goods and services, such as travel, have fallen. The future progression of the outbreak and its effects on our business and operations are uncertain. We may face difficulties recruiting or retaining patients in our ongoing and planned clinical trials if patients are affected by the virus or are fearful of traveling to our clinical trial sites because of the outbreak. We and our third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to our research and development activities, including, for example, medical and laboratory supplies used in our clinical trials or preclinical studies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak. While expected to be temporary, these disruptions may negatively impact the Company’s sales, its results of operations, financial condition, and liquidity in 2021 and potentially beyond.	Note 6. Commitments and Contingencies Employment Agreements The Company has an employment agreement with the Chief Executive Officer, effective September 18, 2018. The agreement may be terminated by either party at any time upon written notice provided to the other party. Concurrent with the employment agreement, the CEO and the Company agreed to an Executive Confidentiality Agreement that contains standard non-closure and non-competition provisions. In the event we terminate the employment agreement other than for cause, or the CEO terminates the agreement for good reason, we will pay the CEO the then effective base salary for a period of twelve months following the effective date of the termination. However, payment of the effective base salary is subject to the execution of a release form and the compliance by the CEO with the release and all terms and provisions of the employment agreement and Executive Confidentiality Agreement that survive the termination of employment. The Company’s Chief Executive Officer has also elected to forego a salary temporarily and defer compensation. Deferred compensation due to the Company’s Chief Executive Officer amounted to $1,005,000 and $630,000 as of December 31, 2020 and 2019, respectively, which is included in accounts payable and accrued expenses on the accompanying balance sheet. Litigation The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows. See also Note 12 – Subsequent Events. Global Pandemic Outbreak In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (“COVID-19”) a global pandemic. The outbreak has become increasingly widespread in the United States, impacting the markets in which the Company operates. While the full impact of the pandemic continues to evolve, the financial markets have been subject to significant volatility that adversely impacts the Company’s ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing initiatives. The uncertain financial markets, disruptions in supply chains, mobility restraints, and changing priorities as well as volatile asset values also affect the Company’s ability to enter into collaborations, joint ventures, and license and royalty agreements. The outbreak and government measures taken in response to the pandemic have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, have spiked, while demand for other goods and services, such as travel, have fallen. The future progression of the outbreak and its effects on our business and operations are uncertain. We may face difficulties recruiting or retaining patients in our ongoing and planned clinical trials if patients are affected by the virus or are fearful of traveling to our clinical trial sites because of the outbreak. We and our third-party contract manufacturers, contract research organizations, and clinical sites may also face disruptions in procuring items that are essential to our research and development activities, including, for example, medical and laboratory supplies used in our clinical trials or preclinical studies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak. While expected to be temporary, these disruptions may negatively impact the Company’s results of operations, financial condition, and liquidity in 2021 and potentially beyond.

Stockholders' Equity

Stockholders' Equity	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Note 7. Stockholders’ Equity Overview Preferred Stock The Company’s Certificate of Incorporation, filed on May 12, 2017, and amended and restated on February 16, 2021, authorizes the issuance of preferred stock. The total number of shares which the Company is authorized to issue is 10,000,000, with a par value of $0.00001 per share. Common Stock The Company’s Certificate of Incorporation, filed on May 12, 2017, and amended and restated on February 16, 2021, authorizes the issuance of common stock. The total number of shares which the Company is authorized to issue is 100,000,000, with a par value of $0.00001 per share. During the six months ended June 30, 2021, the Company issued 1,800,000 shares of common stock related to the Company’s IPO in February 2021, for net proceeds totaling $15,783,207, after deducting underwriting discounts and offering expenses. During the three and six months ended June 30, 2020, the Company issued 85,325 and 128,303 shares of common stock for gross proceeds totaling $425,000 and $1,268,900, respectively. Anthony Mack, the Company’s CEO, and an immediate family member of Mr. Mack purchased 40,450 and 8,393 of these shares of common stock for gross proceeds totaling $400,000 and $83,000, respectively, for the six months ended June 30, 2020. In addition, during the three and six months ended June 30, 2020, the Company issued 113 and 293 shares of common stock in payment of consulting services and settlement of accounts payable totaling $1,125 and $2,906, respectively. Warrants In conjunction with the IPO, the Company granted the underwriters warrants to purchase 90,000 shares of the Company’s common stock at an exercise price of $12.50 per share, which is 125% of initial public offering price. The warrants have a five-year term and are not exercisable prior to August 16, 2021. All of the warrants were outstanding at June 30, 2021 and the fair value allocated to the warrants of $639,000 was accounted for as a component of stockholders’ equity. The fair value of the warrants was estimated using the Black-Scholes option-pricing model and is affected by the Company’s share fair value as well as assumptions regarding a number of complex and subjective variables, including a term of 5 years, expected price volatility of 100%, and a risk-free interest rate of 0.6%. Reverse Stock Split On November 19, 2020, the Company filed an amendment to its Articles of Incorporation and effected 1-for-4.944260256 reverse stock split of its issued and outstanding shares of common stock, $0.00001 par value, whereby 15,550,627 outstanding shares of the Company’s common stock were exchanged for 3,145,153 newly issued shares of the Company’s common stock. Under the terms of the reverse stock split, fractional shares issuable to stockholders were rounded to the nearest whole share, with cash paid in lieu of any fractional shares, resulting in a reverse split of 1-for-4.944260256. All per share amounts and number of shares (other than authorized shares) in the financial statements and related notes have been retroactively restated to reflect the reverse stock split resulting in the transfer of $119 from common stock to additional paid in capital at January 1, 2020.	Note 7. Stockholders’ Equity Overview Preferred Stock The Company’s Certificate of Incorporation, filed on May 12, 2017, authorizes the issuance of preferred stock. The total number of shares which the Company is authorized to issue is 1,000,000, each with a par value of $0.00001 per share. Common Stock The Company’s Certificate of Incorporation, filed on May 12, 2017, authorizes the issuance of common stock. The total number of shares which the Company is authorized to issue is 20,000,000, each with a par value of $0.00001 per share. From inception through December 31, 2020, the Company raised funds through private placements at $9.89 per share. During the year ended December 31, 2020, the Company issued 139,220 shares of common stock for gross proceeds totaling $1,376,900. The Company’s CEO and an immediate family member purchased 40,450 and 8,999 of these shares of common stock for gross proceeds totaling $400,000 and $89,000, respectively. During the year ended December 31, 2019, the Company issued 63,203 shares of common stock for gross proceeds totaling $625,000. The Company’s CEO purchased 60,674 of these shares of common stock for gross proceeds totaling $600,000. In addition, during the year ended December 31, 2020, the Company issued 533 shares of common stock in payment of consulting services and settlement of accounts payable for gross proceeds totaling $5,288. The Company issued 46,903 shares of common stock in payment of consulting services and settlement of accounts payable for gross proceeds totaling $463,815 during the year ended December 31, 2019. Reverse Stock Split On November 19, 2020, the Company filed an amendment to its Articles of Incorporation and effected 1-for-4.944260256 reverse stock split of its issued and outstanding shares of common stock, $0.00001 par value, whereby 15,550,627 outstanding shares of the Company’s common stock were exchanged for 3,145,153 newly issued shares of the Company’s common stock. Under the terms of the reverse stock split, fractional shares issuable to stockholders were rounded to the nearest whole share, with cash paid in lieu of any fractional shares, resulting in a reverse split of 1-for-4.944260256. All per share amounts and number of shares (other than authorized shares) in the financial statements and related notes have been retroactively restated to reflect the reverse stock split resulting in the transfer of $119 and $113 from common stock to additional paid in capital at January 1, 2020 and 2019, respectively.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 8. Stock-Based Compensation Restricted Stock Awards On May 20, 2017, the Company established the Virpax Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (the “Plan”). The Company’s Board of Directors (the “Board”), acting through its Equity Incentive Plan Committee, has determined that it would be to the advantage and best interest of the Company and its stockholders to grant restricted stock awards to certain individuals as compensation to serve as an employee of the Company and as an incentive for increased efforts during such service. There were 14,723 and 5,506 unvested restricted stock awards issued totaling $83,888 and $50,000 based on a fair value of the Company’s common stock on the date of grant, as of June 30, 2021 and December 31, 2020, respectively. During the three months ended June 30, 2021 and 2020, there were 15,000 and 3,160 restricted stock awards granted during the period, respectively, and 20,225 of restricted stock awards forfeited during the three months ended June 30, 2020. The Company recognized $4,688 and $156,250 of stock based compensation for vested restricted shares during the three months ended June 30, 2021 and June 30, 2020, respectively. In addition, during the six months ended June 30, 2021 and 2020, there were 15,000 and 6,952 restricted stock awards granted during the period, respectively, and 20,225 of restricted stock awards forfeited during the six months ended June 30, 2020. The Company recognized $34,629 and $156,250 of stock based compensation for vested restricted shares during the six months ended June 30, 2021 and June 30, 2020, respectively. Stock Options The Plan provides a means for eligible employees, officers, non-employee directors and other individual service providers (collectively, “eligible persons”) to develop a sense of proprietorship and personal involvement in the development and financial success of the Company and to encourage them to devote their best efforts to the business of the Company, thereby advancing the interests of the Company and its stockholders. The Company, by means of the Plan, seeks to retain the services of such eligible persons and to provide incentives for such eligible persons to exert maximum efforts for the success of the Company. The Plan commenced on May 20, 2017 (the “Effective Date”) and is administered by the Compensation Committee of the Board (the “Compensation Committee”); provided that the entire Board may act in lieu of the Compensation Committee on any matter. The maximum aggregate number of shares of common stock which may be issued under all awards granted to participants under the Plan initially shall be 303,382 shares. The number of authorized shares available for issuance under the Plan shall automatically increase on January 1 st st th On April 25, 2020, the Company amended and restated the Plan to grant stock options to non-employee directors. Stock options to purchase 20,225 shares of common stock shall automatically be granted under the Plan to each non-employee director who is first appointed or elected to the Board. In addition, On January 1 of each year, each then serving non-employee director of the Company shall automatically be granted under the Plan (i) that number of options having a value of $25,000 calculated on the grant date in accordance with the Black-Scholes option pricing model and shall be exercisable as to 100% of the number of shares of common stock covered thereby on the twelve-month anniversary of the grant date, and shall have an exercise price equal to 100% of the Fair Market Value (as defined in the Plan) of a share of Common Stock on the date of grant. Also, on January 1 of each year, each then serving member of the Science and Technology Committee of the Board (the “Science and Technology Committee”) shall automatically be granted stock options to purchase 2,022 shares of Common Stock under the Plan, and the Chair of the Science and Technology Committee shall be granted stock options to purchase an additional 3,033 shares of Common Stock under the Plan. These options have the same terms and conditions as the options granted to the non-employee directors noted above. The options due on January 1, 2021 pursuant to the Plan were granted by the Board on April 7, 2021. On April 7, 2021, the Board, upon recommendation of the Company’s Compensation Committee, approved equity compensation awards for the Company’s executive officers, employees and consultants. The Board approved awards of options to purchase 197,500 shares of Common Stock to officers of the Company pursuant to the 2017 Plan. The options have an exercise price of $4.62 per share, the fair market value of the Common Stock on the date of grant of April 7, 2021. The options granted to the officers will vest in three equal annual installments, commencing on the one-year anniversary of the grant date, and have a ten-year expiration date. The grant date fair value of these options using the Black-Scholes option pricing model was $612,050. The Board also approved awards of 52,922 options to the Company’s non-employee directors pursuant to the 2017 Plan. These options have exercise prices of $4.62, the fair market value of the common stock on the date of grant as of April 7, 2021, and will fully vest upon the one-year anniversary of the grant date, and have a ten-year expiration date. The grant date fair value of these options using the Black-Scholes option pricing model was $162,156. Stock-based compensation expense for the three months ended June 30, 2021 and 2020 was $321,427 and $571,691, respectively. The Company recorded $302,993 and $571,691 of this stock-based compensation within general and administrative expense and $18,433 and $0 within research and development expense on the accompanying statement of operations for the three months ended June 30, 2021 and 2020, respectively. Stock-based compensation expense for the six months ended June 30, 2021 and 2020 was $691,310 and $702,681, respectively. The Company recorded $672,877 and $702,681 of this stock-based compensation within general and administrative expense and $18,433 and $0 within research and development expense on the accompanying statement of operations for the six months ended June 30, 2021and 2020, respectively. The fair value of option awards is estimated using the Black-Scholes option-pricing model. Exercise price of each award is generally not less than the per share fair value in effect as of that award date. The determination of fair value using the Black-Scholes model is affected by the Company’s share fair value as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, risk-free interest rate and projected employee share option exercise behaviors. Options granted or modified under the Plan during the six months ended June 30, 2021 and 2020 were valued using the Black-Scholes option-pricing model with the following weighted-average assumptions: For the Six 2021 2020 Expected term (years) 5.77 5.24 Risk-free interest rate 1.05 % 0.49 % Expected volatility 79.40 % 68.47 % Expected dividend yield 0.00 % 0.00 % The Company estimates its expected volatility by using a combination of historical share price volatilities of similar companies within our industry. The risk-free interest rate assumption is based on observed interest rates for the appropriate term of the Company’s options on a grant date. The expected option term assumption is estimated using the simplified method and is based on the mid-point between vest date and the remaining contractual term of the option, since the Company does not have sufficient exercise history to estimate expected term of its historical option awards. The following is a summary of stock option activity under the stock option plan for the six months ended June 30, 2021 and for the year ended December 31, 2020: Number of Weighted- Weighted- Aggregate Options outstanding at January 1, 2020 236,458 $ 9.89 8.96 $ - Forfeited (20,225 ) 9.89 Cancelled - - Granted 269,868 9.89 Options outstanding at December 31, 2020 486,101 9.89 8.68 - Forfeited - - Cancelled - - Granted 250,492 4.62 - - Options outstanding at June 30, 2021 736,593 $ 8.10 8.73 $ - Options exercisable at June 30, 2021 502,197 $ 9.58 8.27 $ - The weighted-average grant-date fair value of stock options granted during the six months ended June 30, 2021 and year ended December 31, 2020 was $3.09 and $5.66, respectively. As of June 30, 2021, there was $665,560 of total time-based unrecognized compensation costs related to unvested stock options stock. These costs are expected to be recognized over a weighted average period of 2.24 years.	Note 8. Stock-Based Compensation Restricted Stock Awards On May 20, 2017, the Company established the Virpax Pharmaceuticals, Inc. Amended and Restated 2017 Equity Incentive Plan (the “Plan”). The Company’s Board of Directors, acting through its Equity Incentive Plan Committee, has determined that it would be to the advantage and best interest of the Company and its stockholders to grant restricted stock awards to certain individuals as compensation to serve as an employee of the Company and as an incentive for increased efforts during such service. As of December 31, 2020, there were 5,056 unvested restricted stock awards issued totaling $50,000 of unearned deferred stock based compensation, based on a fair value of stock of $9.89 per share. In addition, during the year ended December 31, 2020, there were 6,952 restricted stock awards granted and 20,225 of restricted stock awards forfeited during the period. Also, during the year ended December 31, 2020, there were 15,800 restricted stock awards that vested resulting in $156,250 in stock-based compensation expense during the year. As of December 31, 2019, there were 34,130 restricted stock awards issued and unvested totaling $337,500 of unearned deferred stock based compensation, based on a fair value of stock of $9.89 per share. Stock Options The Company’s Plan provides a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietorship and personal involvement in the development and financial success of the Company and to encourage them to devote their best efforts to the business of the Company, thereby advancing the interests of the Company and its stockholders. The Company, by means of the Plan, seeks to retain the services of such eligible persons and to provide incentives for such persons to exert maximum efforts for the success of the Company. The Plan commenced on the Effective Date and the Plan is administered by the Compensation Committee (“Committee”); provided that the entire Board may act in lieu of the Committee on any matter. The maximum aggregate number of shares of common stock which may be issued under all Awards granted to Participants under the Plan initially shall be 303,382 shares. The number of authorized shares available for issuance under the Plan shall automatically increase on January 1 st st th On May 21, 2018, the Company amended the Plan to grant stock options to Non-Employee Directors. Stock options to purchase 5,056 shares of common stock shall automatically be granted under the Plan to each Non-Employee Director who is first appointed or elected to the Board. In addition, On January 1 of each year, each then serving Non-Employee Director of the Company shall automatically be granted under the Plan (i) that number of options having a value of $25,000 calculated on the grant date in accordance with the Black-Scholes option pricing model and shall be exercisable as to 100% of the number of shares of Stock covered thereby on the twelve-month anniversary of the grant date, and shall have an exercise price equal to 100% of the Fair Market Value of a share of Common Stock on the Date of Grant. Also, on January 1, of each year, each then serving member of the Science and Technology Committee shall automatically be granted stock options to purchase 2,022 shares of Common Stock under the Plan, and the Chair of the Science and Technology Committee shall be granted stock options to purchase an additional 3,033 shares of Common Stock under the Plan. These options have the same terms and conditions as the Non-Employee Directors noted above. Stock-based compensation expense for the year ended December 31, 2020 and 2019 was $1,473,642 and $678,146, respectively, which is included in general and administrative expense on the accompanying statement of operations. The fair value of option awards is estimated using the Black-Scholes option-pricing model. Exercise price of each award is generally not less than the per share fair value in effect as of that award date. The determination of fair value using the Black-Scholes model is affected by the Company’s share fair value as well as assumptions regarding a number of complex and subjective variables, including expected price volatility, risk-free interest rate and projected employee share option exercise behaviors. Options granted or modified under the Plan during the years ended December 31, 2020 and 2019 were valued using the Black-Scholes option-pricing model with the following weighted-average assumptions: For the Years Ended 2020 2019 Expected term (years) 5.24 5.54 Risk-free interest rate 0.48 % 2.03 % Expected volatility 68.50 % 57.23 % Expected dividend yield 0.00 % 0.00 % The Company estimates its expected volatility by using a combination of historical share price volatilities of similar companies within our industry. The risk-free interest rate assumption is based on observed interest rates for the appropriate term of the Company’s options on a grant date. The expected option term assumption is estimated using the simplified method and is based on the mid-point between vest date and the remaining contractual term of the option, since the Company does not have sufficient exercise history to estimate expected term of its historical option awards. The following is a summary of stock option activity under the stock option plans for the years ended December 31, 2020 and 2019: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Options outstanding at January 1, 2019 136,515 $ 9.89 9.51 $ — Forfeited (30,337 ) 9.89 Cancelled (5,056 ) 9.89 Granted 135,336 9.89 Options outstanding at December 31, 2019 236,458 9.89 8.96 — Forfeited (20,225 ) 9.89 Granted 269,868 9.89 Options outstanding at December 31, 2020 486,101 $ 9.89 8.68 $ — Options exercisable at December 31, 2020 266,164 $ 9.89 8.15 $ — The weighted-average grant-date fair value of stock options granted during the years ended December 31, 2020 and 2019 was $5.66 and $5.21, respectively. As of December 31, 2020, there was $547,693 of total time-based unrecognized compensation costs related to unvested stock options stock. These costs are expected to be recognized over a weighted average period of 0.50 years. On June 15, 2020, the Company and Michele Linde entered into a consulting agreement in conjunction with Ms. Linde separating from the Company as Executive Vice President, General Counsel and Corporate Secretary of the Company with an effective date of May 15, 2020. As part of the consulting agreement, Ms. Linde agreed to perform consulting and advisory services in exchange for 40,450 nonqualified stock options in the Company pursuant to a nonqualified stock option grant. The options shall vest evenly over a six-month term beginning on the effective date. The options from the consulting agreement were granted in exchange for the forfeiture of the 20,225 unvested restricted stock award and 15,169 unvested nonqualified stock options that were originally granted on October 30, 2019. These modifications are treated as an option modification and the Company accounted for the option modification under ASC Topic 718, Compensation — Stock Compensation. The fair value of the forfeited options and restricted stock award was determined to be in excess of the fair value of the options granted from the consulting agreement. As a result, the fair value of the forfeited options and restricted stock award were recognized over the six-month term of the consulting award, beginning with the effective date. On June 15, 2020, the Company and Ms. Linde also executed an amendment with an effective date of May 15, 2020 to modify three nonqualified stock option grant agreements (the “NQSO Amendment”) that were entered into on July 20, 2018, May 18, 2019, and October 30, 2019, respectively. The nonqualified stock option grants were for 5,056, 10,112, and 5,056 options, respectively. The NQSO Amendment extended the post-termination exercisability period of the vested nonqualified stock options held by Ms. Linde from 90 days following termination of employment to ten years after the initial option grant. The NQSO Amendment also amended the May 19, 2019 grant agreement to vest all 10,112 options on May 18, 2020, regardless if Ms. Linde was employed by the Company at that date. These modifications are treated as an option modification and the Company accounted for the option modification under ASC Topic 718, Compensation — Stock Compensation. As a result of the modification, the Company recognized $90,050 in incremental compensation expense during year ended December 31, 2020.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 9. Income Taxes Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, the Company recorded a valuation allowance to fully offset the gross deferred tax asset, because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets at December 31, 2020 and 2019. During the years ended December 31, 2020 and 2019, there was no income tax expense. Significant components of the Company’s deferred tax assets at December 31, 2020 and 2019: December 31, 2020 December 31, Deferred tax assets: Net-operating loss carryforwards $ 2,008,000 $ 1,267,000 Stock-based compensation 688,000 307,000 Accrued payroll 297,000 197,000 R&D credit 10,000 10,000 Other 77,000 45,000 Total deferred tax assets 3,080,000 1,826,000 Valuation allowance (3,080,000 ) (1,826,000 ) Net deferred tax asset $ — $ — The change in the valuation allowance for the years ended December 31, 2020 and 2019 was an increase of $1,254,000 and 954,000, respectively. The Company’s reconciliation of the federal statutory tax rate and the effective tax rates for the years ended December 31, 2020 and 2019 is as follows: December 31, December 31, Federal statutory rate 21.0 % 21.0 % Increase (decrease) in tax expense at federal statutory rate Change in valuation allowance -21.0 % -20.9 % Other - -0.1 % Effective tax rate 0.0 % 0.0 % The Company had approximately $6,951,000 of gross net operating loss (“NOL”) carryforwards, for both federal and state, as of December 31, 2020. Sections 382 and 383 of the Internal Revenue Code, and similar state regulations, contain provisions that may limit the NOL carryforwards available to be used to offset income in any given year upon the occurrence of certain events, including changes in the ownership interests of significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the NOL carryforwards that the Company may utilize in any one year may be limited. From the total of the Company’s federal NOL of $6,951,000, $326,000 expires in 2037, and the remaining NOL has an indefinite carryover period. The Company’s state NOL’s of $6,951,000 expire from 2037 through 2040. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was signed into law to address the COVID-19 crisis. The CARES Act is an approximately $2 trillion emergency economic stimulus package that includes numerous U.S. federal income tax provisions, including the modification of: (i) net operating loss rules, (ii) the alternative minimum tax refund and (iii) business interest deduction limitations under Section 163(j) of the Internal Revenue Code of 1986, as amended, or the Code. The effects of this legislation will be taken into consideration in the period of enactment in 2020. The changes in federal tax will not have a material effect on the tax liability of the Company.

Related-Party Transactions

Related-Party Transactions	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Related-Party Transactions	Note 9. Related-Party Transactions As discussed in Note 5, in October 2018 and January 2019 the Company issued notes with an aggregate principal amount of $1,000,000. These notes were issued to Anthony Mack, Chief Executive Officer and significant investor of the Company. In addition, in January 2021, the Company issued notes with an aggregate principal amount of $75,000 and $25,000, respectively. These notes were issued to Anthony Mack, Chief Executive Officer and significant investor of the Company for $75,000 and Christopher Chipman, Chief Financial Officer, for $25,000, and were paid off with the proceeds from the initial public offering. As discussed in Note 6, the Company’s Chief Executive Officer elected to temporarily defer his salary. Deferred compensation due to the Company’s Chief Executive Officer amounted to $1,052,000 and $1,005,000 as of June 30, 2021 and December 31, 2020, respectively, which is included in accounts payable and accrued expenses on the accompanying condensed balance sheets. In March 2021, the Company’s Chief Executive Officer ceased deferring compensation.	Note 10. Related-Party Transactions As discussed in Note 5, in October 2018 and January 2019 the Company issued notes with an aggregate principal amount of $1,000,000. These notes were issued to Anthony Mack, Chief Executive Officer and significant investor of the Company. As discussed in Note 3, the Company maintained an account receivable, related party balance as of December 31, 2019. This amount related to the reimbursement due back to the Company for healthcare insurance on behalf of Jeffrey Gudin, the Company’s Chief Medical Officer.

Research and Development and Li

Research and Development and License Agreements	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Research and Development [Abstract]
Research and Development and License Agreements	Note 10. Research and Development and License Agreements MedPharm Limited Research and Option Agreement On April 11, 2017, the Company entered into a research and option agreement, as amended on May 30, 2018 (the “MedPharm Research and Option Agreement”), with MedPharm Limited, a company organized and existing under the laws of the United Kingdom (“MedPharm”), pursuant to which MedPharm granted the Company an option to obtain an exclusive, world-wide, royalty bearing license to use certain technology developed by MedPharm. Pursuant to the agreement, MedPharm will conduct certain research and development of proprietary formulations incorporating certain MedPharm technologies and certain of the Company’s proprietary molecules. Under the MedPharm Research and Option Agreement, MedPharm granted the Company an option (the “MedPharm Option”) to obtain an exclusive (even to MedPharm), worldwide, sub-licensable (through multiple tiers), royalty bearing, irrevocable license to research, develop, market, commercialize, and sell any product utilizing MedPharm’s spray formulation technology which is the result of the activities performed under the MedPharm Research and Option Agreement, subject to the Company’s entry into a definitive license agreement with MedPharm. In order to exercise the MedPharm Option, the Company must provide MedPharm with written notice of such exercise before the end of the Option Period (as defined in the MedPharm Research and Option Agreement). The Option Period is subject to extension upon mutual agreement with MedPharm. Pursuant to the MedPharm Research and Option Agreement, the Company has a right of first refusal with respect to any license or commercial arrangement involving any Licensed Intellectual Property (as defined in the MedPharm Research and Option Agreement) in combination with any Virpax Molecule (as defined in the MedPharm Research and Option Agreement). In the event that MedPharm reaches an agreement with respect to a license or other commercial arrangement that involves technology or molecules covered by the right of first refusal, the Company has ten business days from the date of notice to notify MedPharm of its intention to exercise the right of first refusal and the Company’s intention to match the financial terms of the other license or commercial arrangement. License Agreement On June 6, 2017, as a result of the Company’s exercise of the MedPharm Option under the MedPharm Research and Option Agreement, the Company entered into a license agreement, as amended on September 2, 2017 and October 31, 2017 (the “MedPharm License Agreement”), with MedPharm for the exclusive global rights to discover, develop, make, sell, market, and otherwise commercialize any pharmaceutical composition or preparation (in any and all dosage forms) in final form containing one or more compounds, including Epoladerm and OSF200, that was developed, manufactured or commercialized utilizing MedPharm’s spray formulation technology (“MedPharm Product”), to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses). Under the MedPharm License Agreement, the Company is required to make future milestone and royalty payments to MedPharm. We are obligated to make aggregate milestone payments to MedPharm of up to GBP 1.150 million upon the achievement of specified development milestones (payable in Great British Pounds). Additional milestone payments are due upon the achievement of certain development and commercial milestones achieved outside the United States, payable on a country by country basis. Royalty payments must be paid to MedPharm in an amount equal to a single-digit percentage of net sales of all MedPharm Product sold by us during the royalty term in the territory. Royalties shall be payable, on a country-by-country basis, during the period of time commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on December 4, 2028. Each party has the right to terminate the agreement in its entirety upon written notice to the other party if such other party is in material breach of the agreement and has not cured such breach within ninety (90) days after notice from the terminating party indicating the nature of such breach. LipoCureRx, Ltd. On March 19, 2018, the Company entered into a license and sublicense agreement (the “LipoCure Agreement”) with LipoCureRx, Ltd., a company organized and existing under the laws of Israel (“LipoCure”), for the sole and exclusive global license and sub-license rights to discover, develop, make, sell, market, and otherwise commercialize bupivacaine liposome, in injectable gel or suspension (“Licensed Compound”) or any pharmaceutical composition or preparation (in any and all dosage forms) in final form, including any combination product, containing a Licensed Compound (“Licensed Product”), including Probudur. Under the LipoCure Agreement, the Company was required to pay an upfront fee upon signing of $150,000 and is required to make future milestone and royalty payments to LipoCure. The Company is obligated to make aggregate milestone payments of up to $19.8 million upon the achievement of specified development and commercial milestones. Royalty payments must be paid in an amount equal to a single digit to low double-digit percentage of annual net sales of royalty qualifying products, subject to certain adjustments. Royalties shall be payable during the period of time, on a country-by-country basis, commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on July 24, 2030. Each party has the right to terminate the agreement in its entirety upon written notice to the other party if such other party is in material breach of the agreement and has not cured such breach within ninety (90) days after notice from the terminating party indicating the nature of such breach. Nanomerics Ltd. Nanomerics Collaboration Agreement On April 11, 2019, the Company entered into an exclusive collaboration and license agreement, as amended (the “Nanomerics Collaboration Agreement”), with Nanomerics Ltd., a company organized and existing under the laws of United Kingdom (“Nanomerics”), for the exclusive world-wide license to develop and commercialize products, including NES100, which contain hydrophilic neuropeptide Leucin5-Enkephalin and an amphiphile compound which is quaternary ammonium palmitoyl glycol chitosan, to engage in a collaborative program utilizing Nanomerics’ knowledge, skills and expertise in the clinical development of products and to attract external funding for such development. The Nanomerics Collaboration Agreement was also amended to include a program for the pre-clinical development of a product for post-traumatic stress disorder. Under the Nanomerics Collaboration Agreement, the Company is required to make royalty payments equal to a single digit percentage of annual net sales of royalty qualifying products. The Company is also required to make aggregate milestone payments of up to $103 million upon the achievement of specified development and commercial milestones, and sublicense fees for any sublicense relationships we enter into subsequent to the Nanomerics Collaboration Agreement. The Company’s obligation to pay royalties, on a country-by-country basis, shall commence on the date of first commercial sale of its licensed products and shall expire with respect to each separate licensed product, on the latest to occur of (a) the tenth (10 th Nanomerics License Agreement On August 7, 2020, the Company entered into a collaboration and license agreement with Nanomerics (the “Nanomerics License Agreement”) for the exclusive North American license to develop and commercialize a High-Density Molecular Masking Spray (MMS019) as an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans. Under the Nanomerics License Agreement, the Company is required to make royalty payments within a range of 5% to 15% of annual net sales of royalty qualifying products. The Company’s obligation to pay royalties, on a country-by-country basis, shall commence on the date of first commercial sale of its licensed products and shall expire with respect to each separate licensed product, on the latest to occur of (a) the tenth (10 th Research Agreements Yissum On May 12, 2019, the Company entered into an Agreement for Rendering of Research Services (the “May 2019 Yissum Research Agreement”), with Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (“Yissum”). Under the May 2019 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation, preparation and characterization of Liposomal Bupivacaine for size zeta potential, drug loading and rate of drug release. In consideration for the research services, the Company agreed to pay research service fees of $81,000 in equal monthly installments. The Company retains ownership in all its intellectual property rights and any intellectual property belonging to either the Company or Yissum prior to the execution of the May 2019 Yissum Research Agreement will remain the sole property of either the Company or Yissum, respectively. All data generated from the provision of the May 2019 Yissum Research Agreement, including any reports, which are specifically required and contemplated under the May 2019 Yissum Research Agreement, shall be owned by the Company upon full payment of the research services fees. Each party will be entitled to terminate the agreement in the event of a breach by the other party of its obligations under the agreement, including, but not limited to, any payment failure, which is not remedied by the breaching party within thirty (30) days of receipt of written notice from the non-breaching party. All services to be provided under the May 2019 Yissum Research Agreement were completed by March 31, 2020. On October 11, 2020, the Company entered into an Agreement for Rendering of Research Services with Yissum (the “October 2020 Yissum Research Agreement”) on substantially similar terms and conditions as detailed above under the May 2019 Yissum Research Agreement. Under the October 2020 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation of Liposomal Bupivacaine as well as efficacy and PK studies in animals. In consideration for the research services, the Company agreed to pay research service fees of $81,000 in six equal monthly installments. In connection with the completion of the Company’s IPO, the Company paid Yissum $40,500 towards the total consideration of $81,000. All services to be provided under the October 2020 Yissum Research Agreement were completed by June 30, 2021. On June 30, 2021, the Company entered into an Agreement for Rendering of Research Services with Yissum (the “June 2021 Yissum Research Agreement”) on substantially similar terms and conditions as detailed above under the October 2020 Yissum Research Agreement. Under the June 2021 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the optimization of the Liposomal Bupivacaine formulation and to increase stability for manufacturing purposes. The Company may terminate the agreement at any time and shall be only responsible to pay Yissum for work performed through the date of termination. In consideration for the research services, the Company agreed to pay research service fees of $337,500 in six equal quarterly installments. All services to be provided under the June 2021 Yissum Research Agreement initiated on July 1, 2021 and are anticipated to be completed towards the end 2022. Lipocure On June 29, 2021, the Company entered into an Agreement for Rendering of Research Services (the “June 2021 Lipocure Research Agreement”) with Lipocure RX, Ltd. (“Lipocure”). Under the June 2021 Lipocure Research Agreement, the Company shall provide funding for research and development related to the optimization of the Liposomal Bupivacaine formulation and eventual manufacture of pre-clinical batches including batches for stability testing, animal studies and toxicology work. This will also include work associated with the potential filing of additional provisional patent applications. The Company may terminate the agreement at any time upon 30 days written notice and shall be only responsible to pay Lipocure for work performed through the date of such notice. In consideration for the research services, the Company agreed to pay research service fees of $200,000 upon execution as prepayment for research services included in Prepaid Expenses and Other Current Assets on the accompanying balance sheet as of June 30, 2021, as well as $400,000 on July, 1 2021, and five quarterly payments of $270,000 initiating on September 1 2021. The Company also agreed to pay $250,000 to Lipocure upon successful completion of a Chemistry, Manufacturing and Controls “CMC” filing with the U.S. Food and Drug Administration (the (“FDA”). All services to be provided under the June 2021 Lipocure Research Agreement initiated on July 1, 2021 and are anticipated to be completed towards the end 2022. NCATS-NIH Cooperative Research and Development Agreement On August 25, 2020, the Company entered into a Cooperative Research and Development Agreement (“CRADA”) with the National Center for Advancing Translational Science (“NCATS”). This collaboration is for the continued development of the Company’s product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain. The term of the CRADA is for a period of four years from May 6, 2020 (the effective date of the agreement) and can be terminated by both parties at any time by mutual written consent. In addition, either party may unilaterally terminate the CRADA at any time by providing written notice of at least sixty (60) days before the desired termination date. The agreement provides for studies that are focused on the pre-clinical characterization of NES100 as a novel analgesic for acute and chronic non-cancer pain, and for studies to further develop NES100 through investigative new drug (“IND”) enabling studies. There are certain development “Go/No Go” provisions within the agreement whereby, if certain events occur, or do not occur, NCATS may terminate the CRADA. These “No GO” provisions include: i) lack of efficacy in all animal pain models, ii) no reliable and sensitive bioanalytical method can be developed, iii) manufacturing failure due to inherent process scalability issues, iv) unacceptable toxicity or safety profile to enable clinical dosing, and v) inability to manufacture the NES100 dosage form. With respect to NCATS rights to any invention made solely by an NCATS employee(s) or made jointly by an NCATS employee(s) and our employee(s), the CRADA grants to the Company an exclusive option to elect an exclusive or nonexclusive commercialization license. For inventions owned solely by NCATS or jointly by NCATS and the Company, and licensed pursuant to the Company’s option, the Company must grant to NCATS a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the invention practiced throughout the world by or on behalf of the United States government. For inventions made solely by an employee of the Company, we grant to the United States government a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the invention practiced throughout the world by or on behalf of the United States government for research or other government purposes.	Note 11. Research and Development and License Agreements MedPharm Limited Research and Option Agreement On April 11, 2017, the Company entered into a research and option agreement, as amended on May 30, 2018 (the “MedPharm Research and Option Agreement”), with MedPharm Limited, a company organized and existing under the laws of the United Kingdom (“MedPharm”), pursuant to which MedPharm granted the Company an option to obtain an exclusive, world-wide, royalty bearing license to use certain technology developed by MedPharm. Pursuant to the agreement, MedPharm will conduct certain research and development of proprietary formulations incorporating certain MedPharm technologies and certain of the Company’s proprietary molecules. Under the MedPharm Research and Option Agreement, MedPharm granted the Company an option (the “MedPharm Option”) to obtain an exclusive (even to MedPharm), worldwide, sub-licensable (through multiple tiers), royalty bearing, irrevocable license to research, develop, market, commercialize, and sell any product utilizing MedPharm’s spray formulation technology which is the result of the activities performed under the MedPharm Research and Option Agreement, subject to the Company’s entry into a definitive license agreement with MedPharm. In order to exercise the MedPharm Option, the Company must provide MedPharm with written notice of such exercise before the end of the Option Period (as defined in the MedPharm Research and Option Agreement). The Option Period is subject to extension upon mutual agreement with MedPharm. Pursuant to the MedPharm Research and Option Agreement, the Company has a right of first refusal with respect to any license or commercial arrangement involving any Licensed Intellectual Property (as defined in the MedPharm Research and Option Agreement) in combination with any Virpax Molecule (as defined in the MedPharm Research and Option Agreement). In the event that MedPharm reaches an agreement with respect to a license or other commercial arrangement that involves technology or molecules covered by the right of first refusal, the Company has ten business days from the date of notice to notify MedPharm of its intention to exercise the right of first refusal and the Company’s intention to match the financial terms of the other license or commercial arrangement. License Agreement On June 6, 2017, as a result of the Company’s exercise of the MedPharm Option under the MedPharm Research and Option Agreement, the Company entered into a license agreement, as amended on September 2, 2017 and October 31, 2017 (the “MedPharm License Agreement”), with MedPharm for the exclusive global rights to discover, develop, make, sell, market, and otherwise commercialize any pharmaceutical composition or preparation (in any and all dosage forms) in final form containing one or more compounds, including Epoladerm and OSF200, that was developed, manufactured or commercialized utilizing MedPharm’s spray formulation technology (“MedPharm Product”), to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses). Under the MedPharm License Agreement, the Company is required to make future milestone and royalty payments to MedPharm. We are obligated to make aggregate milestone payments to MedPharm of up to GBP 1.150 million upon the achievement of specified development milestones (payable in Great British Pounds). Additional milestone payments are due upon the achievement of certain development and commercial milestones achieved outside the United States, payable on a country by country basis. Royalty payments must be paid to MedPharm in an amount equal to a single-digit percentage of net sales of all MedPharm Product sold by us during the royalty term in the territory. Royalties shall be payable, on a country-by-country basis, during the period of time commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on December 4, 2028. Each party has the right to terminate the agreement in its entirety upon written notice to the other party if such other party is in material breach of the agreement and has not cured such breach within ninety (90) days after notice from the terminating party indicating the nature of such breach. LipoCureRx, Ltd. On March 19, 2018, the Company entered into a license and sublicense agreement (the “LipoCure Agreement”) with LipoCureRx, Ltd., a company organized and existing under the laws of Israel (“LipoCure”), for the sole and exclusive global license and sub-license rights to discover, develop, make, sell, market, and otherwise commercialize bupivacaine liposome, in injectable gel or suspension (“Licensed Compound”) or any pharmaceutical composition or preparation (in any and all dosage forms) in final form, including any combination product, containing a Licensed Compound (“Licensed Product”), including Probudur. Under the LipoCure Agreement, the Company was required to pay an upfront fee upon signing of $150,000 and are required to make future milestone and royalty payments to LipoCure. The Company is obligated to make aggregate milestone payments of up to $19.8 million upon the achievement of specified development and commercial milestones. Royalty payments must be paid in an amount equal to a single digit to low double-digit percentage of annual net sales of royalty qualifying products, subject to certain adjustments. Royalties shall be payable during the period of time, on a country-by-country basis, commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on July 24, 2030. Each party has the right to terminate the agreement in its entirety upon written notice to the other party if such other party is in material breach of the agreement and has not cured such breach within ninety (90) days after notice from the terminating party indicating the nature of such breach. Nanomerics Ltd. Nanomerics Collaboration Agreement On April 11, 2019, the Company entered into an exclusive collaboration and license agreement, as amended (the “Nanomerics Collaboration Agreement”), with Nanomerics Ltd. (“Nanomerics”), a company organized and existing under the laws of United Kingdom, for the exclusive world-wide license to develop and commercialize products, including NES100, which contain hydrophilic neuropeptide Leucin5-Enkephalin and an amphiphile compound which is quaternary ammonium palmitoyl glycol chitosan, and to engage in a collaborative program utilizing Nanomerics’ knowledge, skills and expertise in the clinical development of products and in attracting external funding for such development. The Nanomerics Collaboration Agreement was also amended to include a program for the pre-clinical development of a product for post-traumatic stress disorder. Under the Nanomerics Collaboration Agreement, the Company required to make royalty payments equal to a single digit percentage of annual net sales of royalty qualifying products. The Company is also required to make aggregate milestone payments of up to $103 million upon the achievement of specified development and commercial milestones, and sublicense fees for any sublicense relationships we enter into subsequent to the Nanomerics Collaboration Agreement. The Company’s obligation to pay royalties, on a country-by-country basis, shall commence on the date of first commercial sale of its licensed products and shall expire with respect to each separate licensed product, on the latest to occur of (a) the tenth (10 th Nanomerics License Agreement On August 7, 2020, the Company entered into a collaboration and license agreement with Nanomerics (the “Nanomerics License Agreement”) for the exclusive North American license to develop and commercialize a High-Density Molecular Masking Spray (MMS019) as an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans. Under the Nanomerics License Agreement, the Company is required to make royalty payments within a range of 5% to 15% of annual net sales of royalty qualifying products. The Company’s obligation to pay royalties, on a country-by-country basis, shall commence on the date of first commercial sale of its licensed products and shall expire with respect to each separate licensed product, on the latest to occur of (a) the tenth (10 th Yissum Research Agreements On May 12, 2019, the Company entered into an Agreement for Rendering of Research Services (the “May 2019 Yissum Research Agreement”), with Yissum. Under the May 2019 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation, preparation and characterization of Liposomal Bupivacaine for size zeta potential, drug loading and rate of drug release. In consideration for the research services, The Company agreed to pay research service fees of $81,000 in equal monthly installments. The Company retains ownership in all our intellectual property rights and any intellectual property belonging to either the Company or Yissum prior to the execution of the May 2019 Yissum Research Agreement will remain the sole property of either the Company or Yissum, respectively. All data generated from the provision of the May 2019 Yissum Research Agreement, including any reports, which are specifically required and contemplated under the May 2019 Yissum Research Agreement, shall be owned by the Company upon full payment of the research services fees. Each party will be entitled to terminate the agreement in the event of a breach by the other party of its obligations under the agreement, including, but not limited to, any payment failure, which is not remedied by the breaching party within 30 days of receipt of written notice from the non-breaching party. All services to be provided under the May 2019 Yissum Research Agreement will be completed by March 31, 2020. On October 11, 2020, the Company entered into an Agreement for Rendering of Research Services with Yissum (the “October 2020 Yissum Research Agreement”) on substantially similar terms and conditions as detailed above in the May 2019 Yissum Research Agreement. Under the October 2020 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation of Liposomal Bupivacaine as well as efficacy and PK studies in animals. In consideration for the research services, the Company agreed to pay research service fees of $81,000 in six equal monthly installments. In connection with the completion of our initial public offering, we paid Yissum $40,500 towards the total consideration of $81,000. All services to be provided under the October 2020 Yissum Research Agreement will be completed by June 30, 2021. NCATS-NIH Cooperative Research and Development Agreement On August 25, 2020, the Company entered into a CRADA with NCATS. This collaboration is for the continued development of its product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain. The term of the CRADA is for a period of four years from the effective date of the agreement and can be terminated by both parties at any time by mutual written consent. In addition, either party may unilaterally terminate the CRADA at any time by providing written notice of at least sixty (60) days before the desired termination date. The agreement provides for studies that are focused on the pre-clinical characterization of NES100 as a novel analgesic for acute and chronic non-cancer pain, and for studies to further develop NES100 through IND enabling studies. There are certain development “Go/No Go” provisions within the agreement whereby, if certain events occur, or do not occur, NCATS may terminate the CRADA. These “No GO” provisions include: i) lack of efficacy in all animal pain models, ii) no reliable and sensitive bioanalytical method can be developed, iii) manufacturing failure due to inherent process scalability issues, iv) unacceptable toxicity or safety profile to enable clinical dosing, and v) inability to manufacture the NES100 dosage form. With respect to NCATS rights to any invention made solely by an NCATS employee(s) or made jointly by an NCATS employee(s) and our employee(s), the CRADA grants to the Company an exclusive option to elect an exclusive or nonexclusive commercialization license. For inventions owned solely by NCATS or jointly by NCATS and the Company, and licensed pursuant to its option, the Company must grant to NCATS a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the invention practiced throughout the world by or on behalf of the United States government. For inventions made solely by an employee of ours, we grant to the United States government a nonexclusive, nontransferable, irrevocable, paid-up license to practice the invention or have the invention practiced throughout the world by or on behalf of the United States government for research or other government purposes.

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 11. Subsequent Events The Company has evaluated subsequent events from the balance sheet date through August 10, 2021. The following are material subsequent events: On July 26, 2021, the Company, based on the recommendation of the Corporate Governance and Nominating Committee, appointed Mr. Gerald Bruce and Mr. Michael Dubin as directors of the Company, effective July 26, 2021, and determined Mr. Dubin qualifies as an “independent director” for purposes of the NASDAQ Capital Market listing standards. On July 26, 2021, the Company’s Board approved an equity compensation award for the Company’s new independent director. The Board approved this award of options (the “Options”) to purchase 20,225 shares of Common Stock to the new director of the Company pursuant to the 2017 Plan. The Options have an exercise price of $4.32 per share, the fair market value of the Common Stock on the date of grant of July 26, 2021. The Options granted to the directors will vest upon the one-year anniversary of the grant date, and have a ten-year expiration date.	Note 12. Subsequent Events The Company has evaluated subsequent events from the balance sheet date through March 31, 2021. The following are material subsequent events: Initial Public Offering On February 16, 2021, the Company closed its initial public offering of 1,800,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $18.0 million, before deducting underwriting discounts and offering expenses, and net proceeds of $16 million. The Company intends to use substantially all of the net proceeds from the offering, after the repayment of notes payable – see below, to fund research and development of its Epoladerm™, Probudur™, Envelta™ and MMS019 indications and other development programs, and for working capital and other general corporate purposes. In conjunction with the initial public offering, the Company amended its Certificate of Incorporation to increase the number of shares of common stock and preferred stock it is authorized to issue to 100,000,000 and 10,000,000, respectively. On February 16, 2021, upon closing the initial public offering, 5,056 restricted stock awards vested totaling $50,000 of stock based compensation. Notes Payable In January 2021, the Company issued notes with an aggregate principal amount of $75,000 and $25,000, respectively. These notes were issued to Anthony Mack, Chief Executive Officer and significant investor of the Company for $75,000 and Christopher Chipman, Chief Financial Officer, for $25,000. These notes were subsequently repaid with proceeds from the initial public offering in February 2021. In February 2021, the Company paid the balance on its RRD Note of $493,480, including accrued interest, with proceeds from the Company’s initial public offering. Legal Proceedings On March 12, 2021, we and Anthony Mack, our President and Chief Executive Officer, were named as defendants in a complaint (the “Complaint”) filed by Sorrento Therapeutics, Inc. (“Sorrento”) and Scilex Pharmaceuticals Inc. (“Scilex” and together with Sorrento, the “Plaintiffs”) in the Court of Chancery of the State of Delaware (the “Court”). In the Complaint the Plaintiffs allege (i) Mr. Mack breached a Restrictive Covenants Agreement, dated as of November 8, 2016, between himself and Sorrento (the “Restrictive Covenants Agreement”), (ii) we tortiously interfered with the Restrictive Covenants Agreement, and (iii) we tortiously interfered with Scilex’s relationship with Mr. Mack. Simultaneously with filing the Complaint, the Plaintiffs filed a motion to expedite, seeking a hearing in four weeks on their prospective motion for a preliminary injunction, prohibiting Mr. Mack’s alleged violations of the Restrictive Covenants Agreement and prohibiting our alleged tortious interference. On March 19, 2021, the parties reached an agreement to schedule the hearing for a date in July 2021, which the Court so ordered. We believe that the allegations in the Complaint and the motion for a preliminary injunction are wholly without merit and we intend to vigorously defend the action. However, we are unable to predict the ultimate outcome of the lawsuit at this time.

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2021
Disclosure Text Block Supplement [Abstract]
Prepaid Expenses and Other Current Assets	Note 3. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consists of the following: June 30, December 31, Prepaid insurance $ 703,316 $ 8,257 Prepaid research and development 200,000 - Legal retainer 3,050 3,643 Consulting fees 8,825 5,838 Other prepaid expenses and current assets 5,731 534 $ 920,922 $ 18,273

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation	Basis of Presentation
Use of Estimates	Use of Estimates Significant items subject to such estimates and assumptions include research and development accruals and the valuation of stock-based compensation. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.	Use of Estimates Significant items subject to such estimates and assumptions include research and development accruals and the valuation of stock-based compensation. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.
Basic and Diluted Loss per Share	Basic and Diluted Loss per Share Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 Six Months Six Months Equivalent common shares Stock options 736,593 486,101 736,593 486,101 Warrants 95,056 — 95,056 — RRD note conversion — 43,909 — 43,909	Basic and Diluted Loss per Share Year Ended Year Ended Equivalent common shares Stock options 486,101 236,458 Warrants 5,056 — RRD note conversion 49,897 26,746
Cash		Cash
Fair Value of Financial Instruments	Fair Value of Financial Instruments	Fair Value of Financial Instruments
Research and Development	Research and Development	Research and Development
Stock-based Compensation	Stock-based Compensation Determining the appropriate fair value of share-based awards requires the use of subjective assumptions, including the fair value of the Company’s common shares, and for options, the expected life of the option and expected share price volatility. The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represents management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. The expected life of options was estimated using the simplified method, as the Company has historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.	Stock-based Compensation Determining the appropriate fair value of share-based awards requires the use of subjective assumptions, including the fair value of the Company’s common shares, and for options, the excepted life of the option and expected share price volatility. The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represents management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. The expected life of options was estimated using the simplified method, as the Company has historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.
Income Taxes	Income Taxes The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of June 30, 2021, the Company had no uncertain income tax positions.	Income Taxes The Company follows the guidance in ASC Topic 740-10 in assessing uncertain tax positions. The standard applies to all tax positions and clarifies the recognition of tax benefits in the financial statements by providing for a two-step approach of recognition and measurement. The first step involves assessing whether the tax position is more-likely-than-not to be sustained upon examination based upon its technical merits. The second step involves measurement of the amount to be recognized. Tax positions that meet the more-likely than-not threshold are measured at the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate finalization with the taxing authority. The Company recognizes the impact of an uncertain income tax position in the financial statements if it believes that the position is more likely than not to be sustained by the relevant taxing authority. The Company will recognize interest and penalties related to tax positions in income tax expense. As of December 31, 2020, the Company had no uncertain income tax positions.
Cash	Cash

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of antidilutive due to the net loss	Three Months Ended June 30, 2021 Three Months Ended June 30, 2020 Six Months Six Months Equivalent common shares Stock options 736,593 486,101 736,593 486,101 Warrants 95,056 — 95,056 — RRD note conversion — 43,909 — 43,909	Year Ended Year Ended Equivalent common shares Stock options 486,101 236,458 Warrants 5,056 — RRD note conversion 49,897 26,746

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Prepaid Expenses And Other Current Assets Disclosure [Abstract]
Schedule of prepaid expenses and other current assets	June 30, December 31, Prepaid insurance $ 703,316 $ 8,257 Prepaid research and development 200,000 - Legal retainer 3,050 3,643 Consulting fees 8,825 5,838 Other prepaid expenses and current assets 5,731 534 $ 920,922 $ 18,273	December 31, December 31, Prepaid insurance $ 8,257 $ 3,328 Legal retainer 3,643 — Consulting fees 5,838 — Accounts receivable, related party - 1,388 Other prepaid expenses and current assets 534 1,855 $ 18,273 $ 5,183

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Schedule of accounts payable and accrued liabilities	June 30, December 31, Deferred CEO compensation $ 1,073,075 $ 1,028,110 Research and development expenses 69,605 1,045,503 Insurance premiums 448,789 2,874 Legal expenses 768,811 437,471 Professional fees 47,748 253,462 Interest payable/accrued 291,406 270,000 Accounting consulting fees 6,235 45,904 Tax expenses 10,000 13,365 Other 64,197 19,235 $ 2,779,866 $ 3,115,924	December 31, December 31, Deferred CEO compensation $ 1,028,110 $ 680,400 Research and development expenses 1,045,505 275,429 Legal expenses 437,471 200,062 Professional fees 253,462 177,096 Interest payable/accrued 270,000 138,762 Accounting consulting fees 45,904 24,765 Taxes 13,365 14,465 Other 22,107 3,495 $ 3,115,924 $ 1,514,474

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of notes payables	June 30, 2021 Balance as of Notes Issued Note Balance as of Related party notes payable Anthony Mack 2018 Promissory Note $ 500,000 $ — $ — $ 500,000 Anthony Mack 2019 Promissory Note 500,000 — — 500,000 Related party notes payable — 100,000 (100,000 ) — Total related party notes payable 1,000,000 100,000 (100,000 ) 1,000,000 RRD Note 493,480 — (493,480 ) — SBA PPP Loan 72,100 — — 72,100 Total notes payable 1,565,580 100,000 (593,480 ) 1,072,100 Less: Current portion of notes payable 543,990 100,000 (593,480 ) 50,510 Total non-current portion of notes payable $ 1,021,590 $ — $ — $ 1,021,590	December 31, 2020 Balance as of Notes Balance as of Related party notes payable Anthony Mack 2018 Promissory Note $ 500,000 $ — $ 500,000 Anthony Mack 2019 Promissory Note 500,000 — 500,000 Total related party notes payable 1,000,000 — 1,000,000 RRD Note 264,520 228,960 493,480 SBA PPP Loan — 72,100 72,100 Total notes payable $ 1,264,520 $ 301,060 $ 1,565,580 Less: Current portion of notes payable 1,264,520 279,470 543,990 Total non-current portion of notes payable $ — $ 21,590 $ 1,021,590 December 31, 2019 Balance as of Notes Balance as of Related party notes payable Anthony Mack 2018 Promissory Note $ 500,000 $ — $ 500,000 Anthony Mack 2019 Promissory Note — 500,000 500,000 Total related party notes payable 500,000 500,000 1,000,000 RRD Note — 264,520 264,520 Total notes payable 500,000 764,520 1,264,520 Less: Current portion of notes payable 500,000 764,520 1,264,520 Total non-current portion of notes payable $ — $ — $ —
Schedule of principal payments on note payables	Years ending December 31, 2021 $ 50,510 2022 21,590 2023 1,000,000 Total payments $ 1,072,100	Years ending December 31, 2021 $ 543,990 2022 21,590 2023 1,000,000 2024 — Total payments $ 1,565,580

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Black-Scholes option-pricing model	For the Six 2021 2020 Expected term (years) 5.77 5.24 Risk-free interest rate 1.05 % 0.49 % Expected volatility 79.40 % 68.47 % Expected dividend yield 0.00 % 0.00 %	For the Years Ended 2020 2019 Expected term (years) 5.24 5.54 Risk-free interest rate 0.48 % 2.03 % Expected volatility 68.50 % 57.23 % Expected dividend yield 0.00 % 0.00 %
Schedule of stock option activity	Number of Weighted- Weighted- Aggregate Options outstanding at January 1, 2020 236,458 $ 9.89 8.96 $ - Forfeited (20,225 ) 9.89 Cancelled - - Granted 269,868 9.89 Options outstanding at December 31, 2020 486,101 9.89 8.68 - Forfeited - - Cancelled - - Granted 250,492 4.62 - - Options outstanding at June 30, 2021 736,593 $ 8.10 8.73 $ - Options exercisable at June 30, 2021 502,197 $ 9.58 8.27 $ -	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Options outstanding at January 1, 2019 136,515 $ 9.89 9.51 $ — Forfeited (30,337 ) 9.89 Cancelled (5,056 ) 9.89 Granted 135,336 9.89 Options outstanding at December 31, 2019 236,458 9.89 8.96 — Forfeited (20,225 ) 9.89 Granted 269,868 9.89 Options outstanding at December 31, 2020 486,101 $ 9.89 8.68 $ — Options exercisable at December 31, 2020 266,164 $ 9.89 8.15 $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of deferred tax assets	December 31, 2020 December 31, Deferred tax assets: Net-operating loss carryforwards $ 2,008,000 $ 1,267,000 Stock-based compensation 688,000 307,000 Accrued payroll 297,000 197,000 R&D credit 10,000 10,000 Other 77,000 45,000 Total deferred tax assets 3,080,000 1,826,000 Valuation allowance (3,080,000 ) (1,826,000 ) Net deferred tax asset $ — $ —
Schedule of reconciliation of the federal statutory tax rate and the effective tax rates	December 31, December 31, Federal statutory rate 21.0 % 21.0 % Increase (decrease) in tax expense at federal statutory rate Change in valuation allowance -21.0 % -20.9 % Other - -0.1 % Effective tax rate 0.0 % 0.0 %

Prepaid Expenses and Other Cu_4

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure Text Block Supplement [Abstract]
Schedule of prepaid expenses and other current assets	June 30, December 31, Prepaid insurance $ 703,316 $ 8,257 Prepaid research and development 200,000 - Legal retainer 3,050 3,643 Consulting fees 8,825 5,838 Other prepaid expenses and current assets 5,731 534 $ 920,922 $ 18,273	December 31, December 31, Prepaid insurance $ 8,257 $ 3,328 Legal retainer 3,643 — Consulting fees 5,838 — Accounts receivable, related party - 1,388 Other prepaid expenses and current assets 534 1,855 $ 18,273 $ 5,183

Business and Liquidity (Details

Business and Liquidity (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Feb. 16, 2021
Business and Liquidity [Line Items]
Incurred a net loss	$ 4,722,690	$ 1,926,279	$ (4,339,653)	$ (3,306,512)
Accumulated deficit	$ 15,370,534		(10,647,844)
Net proceeds			$ 1,376,900	$ 625,000
Issuance of common stock (in Shares)			139,220	63,203
Shares, Issued (in Shares)			303,382
Underwriters warrants to purchase shares (in Shares)	90,000
Exercise price per share (in Dollars per share)	$ 12.50
Percentage of initial public offering price	125.00%
IPO [Member]
Business and Liquidity [Line Items]
Net proceeds			$ 16,000,000
Issuance of common stock (in Shares)			1,800,000
Shares, Issued (in Shares)					1,800,000
Initial offering price per share (in Dollars per share)					$ 10
Gross proceeds	$ 18,000,000
Net proceeds	$ 15,800,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Tax benefit	50.00%	50.00%
Total Cash	$ 10,466,774	$ 54,796

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of antidilutive due to the net loss - shares	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Stock options [Member]
Equivalent common shares
Equivalent common shares	736,593	486,101	736,593	486,101	486,101	236,458
Warrants [Member]
Equivalent common shares
Equivalent common shares	95,056		95,056		5,056
RRD note conversion [Member]
Equivalent common shares
Equivalent common shares		43,909		43,909	49,897	26,746

Prepaid Expenses and Other Cu_5

Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($)	Jun. 30, 2021	Dec. 31, 2020		Dec. 31, 2019
Schedule of prepaid expenses and other current assets [Abstract]
Prepaid insurance	$ 703,316	$ 8,257		$ 3,328
Legal retainer	3,050	3,643
Consulting fees	8,825	5,838
Accounts receivable, related party				1,388
Other prepaid expenses and current assets	5,731	534		1,855
Total prepaid expenses and other current assets	$ 920,922	$ 18,273	[1]	$ 5,183
[1]	Derived from audited financial statements

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities - USD ($)	Jun. 30, 2021	Dec. 31, 2020		Dec. 31, 2019
Schedule of accounts payable and accrued liabilities [Abstract]
Deferred CEO compensation	$ 1,073,075	$ 1,028,110		$ 680,400
Research and development expenses		1,045,505		275,429
Legal expenses		437,471		200,062
Professional fees	47,748	253,462		177,096
Interest payable/accrued	291,406	270,000		138,762
Accounting consulting fees		45,904		24,765
Taxes		13,365		14,465
Other		22,107		3,495
Total accounts payable and accrued liabilities	$ 2,779,866	$ 3,115,924	[1]	$ 1,514,474
[1]	Derived from audited financial statements

Notes Payable (Details)

Notes Payable (Details) - USD ($)	Jul. 02, 2021	Feb. 28, 2021	Jan. 31, 2021	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Nov. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	May 04, 2020	Aug. 29, 2019	Jan. 15, 2019	Dec. 31, 2018	Oct. 01, 2018
Notes Payable (Details) [Line Items]
Principal amount												$ 72,100
Interest rate										6.00%		1.00%
Promissory note					$ 1,072,100		$ 1,072,100			$ 1,565,580	$ 1,264,520				$ 500,000
Accrued interest		$ 34,544							$ 30,431
Interest expense					34,049	$ 43,261	64,748	$ 83,891		147,934	124,644
Interest rate												1.00%
Forgiveness amount	$ 61,816
Repayments of debt	$ 10,284
Notes payable description			the Company issued notes with an aggregate principal amount of $75,000 and $25,000, respectively. These notes were issued to Anthony Mack for $75,000 and Christopher Chipman, Chief Financial Officer, for $25,000. These notes bore interest as a rate of 1.35% per annum and were subsequently repaid with proceeds from the IPO, including accrued interest of $122 and $41, respectively.
Promissory Note 2018 [Member]
Notes Payable (Details) [Line Items]
Principal amount																$ 500,000
Interest rate																11.19%
Promissory note					500,000		500,000			500,000	500,000
Accrued interest							153,862			125,887	74,692
Interest rate																11.19%
Promissory Note 2019 [Member]
Notes Payable (Details) [Line Items]
Principal amount														$ 500,000
Interest rate														11.19%
Promissory note					$ 500,000		500,000			500,000	500,000
Accrued interest							$ 137,544			109,569	56,329
Interest rate														11.19%
RRD International, LLC [Member]
Notes Payable (Details) [Line Items]
Principal amount											493,480		$ 400,000
Accrued interest										34,544	7,741
Fixed rate													10.00%
Interest accrued total				$ 16,435
Convertible note										$ 493,480	264,520
Balance amount on note		$ 528,024
RRD International, LLC [Member] | Minimum [Member]
Notes Payable (Details) [Line Items]
Increased the amount of principal				400,000
RRD International, LLC [Member] | Maximum [Member]
Notes Payable (Details) [Line Items]
Increased the amount of principal				$ 600,000							$ 600,000

Notes Payable (Details) - Sched

Notes Payable (Details) - Schedule of notes payables - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Notes Payable (Details) - Schedule of notes payables [Line Items]
Related party notes payable, Beginning Balance	$ 1,000,000	$ 1,000,000	$ 500,000
Related party notes payable, Notes issued	100,000		500,000
Related party notes payable, Ending Balance	1,000,000	1,000,000	1,000,000
Notes payable, Beginning Balance	1,565,580	1,264,520	500,000
Notes payable, Notes issued	100,000	301,060	764,520
Notes payable, Ending Balance	1,072,100	1,565,580	1,264,520
Less: Current portion of, Beginning Balance	543,990	1,264,520	500,000
Less: Current portion of Notes issued	100,000	279,470	764,520
Less: Current portion of, Ending Balance		543,990	1,264,520
Total non-current portion of notes payable, Beginning Balance	1,021,590
Total non-current portion of notes payable, Notes issued		21,590
Total non-current portion of notes payable, Ending Balance	1,021,590	1,021,590
Anthony Mack 2018 Promissory Note [Member]
Notes Payable (Details) - Schedule of notes payables [Line Items]
Related party notes payable, Beginning Balance	500,000	500,000	500,000
Related party notes payable, Notes issued
Related party notes payable, Ending Balance	500,000	500,000	500,000
Anthony Mack 2019 Promissory Note [Member]
Notes Payable (Details) - Schedule of notes payables [Line Items]
Related party notes payable, Beginning Balance	500,000	500,000
Related party notes payable, Notes issued			500,000
Related party notes payable, Ending Balance	500,000	500,000	500,000
RRD Note [Member]
Notes Payable (Details) - Schedule of notes payables [Line Items]
Notes payable, Beginning Balance	493,480	264,520
Notes payable, Notes issued		228,960	264,520
Notes payable, Ending Balance		493,480	264,520
SBA PPP Loan [Member]
Notes Payable (Details) - Schedule of notes payables [Line Items]
Notes payable, Beginning Balance	72,100
Notes payable, Notes issued		72,100
Notes payable, Ending Balance	$ 72,100	$ 72,100

Notes Payable (Details) - Sch_2

Notes Payable (Details) - Schedule of principal payments on note payables - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Schedule of principal payments on note payables [Abstract]
2021	$ 50,510	$ 543,990
2022	21,590	21,590
2023	1,000,000	1,000,000
2024
Total payments	$ 1,072,100	$ 1,565,580

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies [Abstract]
Deferred compensation	$ 1,052,000	$ 1,005,000
Chief Executive Officer [Member]
Commitments and Contingencies [Abstract]
Deferred compensation		$ 1,005,000	$ 630,000

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Jan. 02, 2020	Jan. 02, 2020	Jan. 02, 2019	Nov. 19, 2020	Feb. 28, 2020	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Feb. 16, 2021
Stockholder's Equity [Abstract]
Preferred stock shares authorized								10,000,000		10,000,000	1,000,000
Preferred stock par value (in Dollars per share)								$ 0.00001		$ 0.00001	$ 0.00001
Common stock shares authorized								100,000,000		100,000,000	20,000,000
Common stock par value (in Dollars per share)								$ 0.00001		$ 0.00001	$ 0.00001
Shares of common stock										139,220	63,203
Common stock gross proceeds (in Dollars)										$ 1,376,900	$ 625,000
Accounts payable gross proceeds (in Dollars)						$ 1,125	$ 1,781			$ 5,288	$ 463,815
Reverse stock split, description				the Company filed an amendment to its Articles of Incorporation and effected 1-for-4.944260256 reverse stock split of its issued and outstanding shares of common stock, $0.00001 par value, whereby 15,550,627 outstanding shares of the Company’s common stock were exchanged for 3,145,153 newly issued shares of the Company’s common stock. Under the terms of the reverse stock split, fractional shares issuable to stockholders were rounded to the nearest whole share, with cash paid in lieu of any fractional shares, resulting in a reverse split of 1-for-4.944260256.
Transfer amount (in Dollars)	$ 119	$ 119	$ 113
Net proceeds (in Dollars)								$ 18,000,000
Common stock shares						85,325			128,303
Gross proceeds (in Dollars)						$ 425,000			$ 1,268,900
Shares issued						113			293
Amount of accounts payable. (in Dollars)						$ 1,125			$ 2,906
Shares of common stock								90,000
Exercise price per share (in Dollars per share)								$ 12.50
Initial public offering price (in Dollars per share)								$ 1.25
Income Tax Effects Allocated Directly to Equity, Cumulative Effect of Change in Accounting Principle (in Dollars)								$ 639,000
Number of complex and subjective variables years								5 years
Price volatility								100.00%
Risk-free interest rate (in Dollars per share)								$ 0.006
Preferred Stock [Member]
Stockholder's Equity [Abstract]
Incorporation filed date										May 12, 2017
Preferred stock shares authorized								10,000,000		1,000,000
Preferred stock par value (in Dollars per share)								$ 0.00001		$ 0.00001
Shares of consulting services
Accounts payable gross proceeds (in Dollars)
Common Stock [Member]
Stockholder's Equity [Abstract]
Common stock shares authorized								100,000,000		20,000,000
Common stock par value (in Dollars per share)								$ 0.00001		$ 0.00001
Shares of consulting services						113	180			533	46,903
Accounts payable gross proceeds (in Dollars)
CEO [Member]
Stockholder's Equity [Abstract]
Shares of common stock									40,450	40,450	60,674
Common stock gross proceeds (in Dollars)									$ 400,000	$ 400,000	$ 600,000
Family Member [Member]
Stockholder's Equity [Abstract]
Shares of common stock									8,393	8,999
Common stock gross proceeds (in Dollars)									$ 83,000	$ 89,000
Private Placements [Memner]
Stockholder's Equity [Abstract]
Price per share (in Dollars per share)										$ 9.89
IPO [Member]
Stockholder's Equity [Abstract]
Price per share (in Dollars per share)												$ 10
Shares of common stock										1,800,000
Common stock gross proceeds (in Dollars)										$ 16,000,000
Shares of common stock								1,800,000
Net proceeds (in Dollars)					$ 15,783,207

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)	Apr. 07, 2021	May 21, 2018	Jun. 15, 2020	Apr. 25, 2020	Oct. 30, 2019	May 18, 2019	Jul. 20, 2018	May 20, 2017	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	May 18, 2020	May 04, 2020
Stock-Based Compensation (Details) [Line Items]
Restricted stock awards, description													There were 14,723 and 5,506 unvested restricted stock awards issued totaling $83,888 and $50,000 based on a fair value of the Company’s common stock on the date of grant, as of June 30, 2021 and December 31, 2020, respectively. During the three months ended June 30, 2021 and 2020, there were 15,000 and 3,160 restricted stock awards granted during the period, respectively, and 20,225 of restricted stock awards forfeited during the three months ended June 30, 2020. The Company recognized $4,688 and $156,250 of stock based compensation for vested restricted shares during the three months ended June 30, 2021 and June 30, 2020, respectively. In addition, during the six months ended June 30, 2021 and 2020, there were 15,000 and 6,952 restricted stock awards granted during the period, respectively, and 20,225 of restricted stock awards forfeited during the six months ended June 30, 2020. The Company recognized $34,629 and $156,250 of stock based compensation for vested restricted shares during the six months ended June 30, 2021 and June 30, 2020, respectively.		there were 5,056 unvested restricted stock awards issued totaling $50,000 of unearned deferred stock based compensation, based on a fair value of stock of $9.89 per share. In addition, during the year ended December 31, 2020, there were 6,952 restricted stock awards granted and 20,225 of restricted stock awards forfeited during the period. Also, during the year ended December 31, 2020, there were 15,800 restricted stock awards that vested resulting in $156,250 in stock-based compensation expense during the year. As of December 31, 2019, there were 34,130 restricted stock awards issued and unvested totaling $337,500 of unearned deferred stock based compensation, based on a fair value of stock of $9.89 per share.
Aggregate number of share issued (in Shares)															303,382
Expiration percentage															6.00%			1.00%
Stock options to purchase common shares (in Shares)		5,056		20,225
Number of stock option based value		$ 25,000
Stock-based compensation exercisable percentage		100.00%		100.00%
Fair market value of common stock percentage		100.00%		100.00%
Additional shares of common stock (in Shares)		3,033		3,033
Share based compensation expense															$ 1,473,642	$ 678,146
Weighted-average grant-date fair value of stock options (in Dollars per share)													$ 3.09		$ 5.66	$ 5.21
Stock based compensation unrecognized costs									$ 665,560				$ 665,560		$ 547,693
Weighted average term													2 years 2 months 26 days		6 months
Stock based nonqualified stock options (in Shares)			40,450		5,056	10,112	5,056
Stock based granted in exchange for the forfeiture			$ 20,225
Unvested restricted stock award (in Shares)			15,169
Stock based options vested (in Shares)																	10,112
Stock-based compensation within research and development expense									$ 18,433		$ 0				$ 90,050
Shares of common stock outstanding, percentage									6.00%				6.00%
Stock option exercise price (in Dollars per share)
Stock-based compensation									$ 321,427	$ 369,884	571,691	$ 130,990			$ 1,473,642	$ 678,146
Stock-based compensation within general and administrative expense									$ 302,993		$ 571,691		$ 672,877	$ 702,681
Share based compensation expense													691,310	702,681
Stock-based compensation within research and development expense													$ 18,433	$ 0
Stock Option [Member]
Stock-Based Compensation (Details) [Line Items]
Stock options to purchase common shares (in Shares)		2,022		2,022
Initial Issuance Under Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Aggregate number of share issued (in Shares)								303,382
Black-Scholes Option Pricing Model [Member]
Stock-Based Compensation (Details) [Line Items]
Number of stock option based value				$ 25,000
Board [Member]
Stock-Based Compensation (Details) [Line Items]
Awards of options to purchase shares of common stock (in Shares)	197,500
Stock option exercise price (in Dollars per share)	$ 4.62
Grant date fair value of options	$ 612,050
Non-Employee Directors [Member]
Stock-Based Compensation (Details) [Line Items]
Awards of options to purchase shares of common stock (in Shares)	52,922
Stock option exercise price (in Dollars per share)	$ 4.62
Grant date fair value of options	$ 162,156

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of Black-Scholes option-pricing model	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Schedule of Black-Scholes option-pricing model [Abstract]
Expected term (years)	5 years 9 months 7 days	5 years 2 months 26 days	5 years 2 months 26 days	5 years 6 months 14 days
Risk-free interest rate	1.05%	0.49%	0.48%	2.03%
Expected volatility	79.40%	68.47%	68.50%	57.23%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of stock option activity - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of stock option activity [Abstract]
Number of Shares, Beginning (in Shares)	486,101	236,458	136,515
Weighted- Average Exercise Price, Beginning	$ 9.89	$ 9.89	$ 9.89
Weighted- Average Remaining Contractual Term (Years), Beginning		8 years 11 months 15 days	9 years 6 months 3 days
Aggregate Intrinsic Value, Beginning (in Dollars)
Number of Shares, Ending (in Shares)		486,101	236,458
Weighted- Average Exercise Price, Ending		$ 9.89	$ 9.89
Weighted- Average Remaining Contractual Term (Years), Ending		8 years 8 months 4 days	8 years 11 months 15 days
Aggregate Intrinsic Value, Ending (in Dollars)
Number of Shares, Options exercisable (in Shares)		266,164
Weighted- Average Exercise Price, Options exercisable		$ 9.89
Weighted- Average Remaining Contractual Term (Years), Options exercisable	8 years 3 months 7 days	8 years 1 month 24 days
Aggregate Intrinsic Value, Options exercisable (in Dollars)
Number of Shares, Forfeited (in Shares)		(20,225)	(30,337)
Weighted- Average Exercise Price, Forfeited		$ 9.89	$ 9.89
Number of Shares, Cancelled (in Shares)			(5,056)
Weighted- Average Exercise Price, Cancelled			$ 9.89
Number of Shares, Granted (in Shares)	250,492	269,868	135,336
Weighted- Average Exercise Price, Granted	$ 4.62	$ 9.89	$ 9.89
Weighted- Average Remaining Contractual Term (Years), Granted
Aggregate Intrinsic Value, Granted

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Valuation allowance increase	$ 1,254,000	$ 954,000
Gross net operating loss (NOL)	$ 6,951,000
NOL carryforward, Description	In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the NOL carryforwards that the Company may utilize in any one year may be limited.
Net operating loss expiration date	From the total of the Company’s federal NOL of $6,951,000, $326,000 expires in 2037, and the remaining NOL has an indefinite carryover period.
Federal NOL amount	$ 6,951,000
Federal NOL amount one	$ 326,000
State NOL's amount	$6,951,000
Net operating loss expiration date one	expire from 2037 through 2040.
Description of economic security act	The CARES Act is an approximately $2 trillion emergency economic stimulus package that includes numerous U.S. federal income tax provisions, including the modification of: (i) net operating loss rules, (ii) the alternative minimum tax refund and (iii) business interest deduction limitations under Section 163(j) of the Internal Revenue Code of 1986, as amended, or the Code. The effects of this legislation will be taken into consideration in the period of enactment in 2020. The changes in federal tax will not have a material effect on the tax liability of the Company

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of deferred tax assets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net-operating loss carryforwards	$ 2,008,000	$ 1,267,000
Stock-based compensation	688,000	307,000
Accrued payroll	297,000	197,000
R&D credit	10,000	10,000
Other	77,000	45,000
Total deferred tax assets	3,080,000	1,826,000
Valuation allowance	(3,080,000)	(1,826,000)
Net deferred tax asset

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of reconciliation of the federal statutory tax rate and the effective tax rates	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of reconciliation of the federal statutory tax rate and the effective tax rates [Abstract]
Federal statutory rate	21.00%	21.00%
Increase (decrease) in tax expense at federal statutory rate
Change in valuation allowance	(21.00%)	(20.90%)
Other		(0.10%)
Effective tax rate	0.00%	0.00%

Related-Party Transactions (Det

Related-Party Transactions (Details) - USD ($)	1 Months Ended			6 Months Ended
	Jan. 31, 2020	Jan. 31, 2019	Oct. 31, 2018	Jun. 30, 2021	Dec. 31, 2020
Related-Party Transactions (Details) [Line Items]
Principal amount		$ 1,000,000	$ 1,000,000
Aggregate principal amount		$ 1,000,000	$ 1,000,000
Christopher Chipman [Member]
Related-Party Transactions (Details) [Line Items]
Aggregate principal amount				$ 25,000
Chief Executive Officer [Member]
Related-Party Transactions (Details) [Line Items]
Deferred compensation				1,052,000	$ 1,005,000
Anthony Mack [Member]
Related-Party Transactions (Details) [Line Items]
Aggregate principal amount	$ 75,000			$ 75,000
Chief Financial Officer [Member]
Related-Party Transactions (Details) [Line Items]
Aggregate principal amount	$ 25,000

Research and Development and _2

Research and Development and License Agreements (Details) - USD ($)	Jul. 02, 2021	Oct. 11, 2020	Aug. 07, 2020	May 12, 2019	Apr. 11, 2019	Jun. 06, 2017	Jun. 30, 2021	Aug. 25, 2020	Mar. 19, 2018	Sep. 01, 2021
Research and Development and License Agreements (Details) [Line Items]
Description of license agreement						the Company’s exercise of the MedPharm Option under the MedPharm Research and Option Agreement, the Company entered into a license agreement, as amended on September 2, 2017 and October 31, 2017 (the “MedPharm License Agreement”), with MedPharm for the exclusive global rights to discover, develop, make, sell, market, and otherwise commercialize any pharmaceutical composition or preparation (in any and all dosage forms) in final form containing one or more compounds, including Epoladerm and OSF200, that was developed, manufactured or commercialized utilizing MedPharm’s spray formulation technology (“MedPharm Product”), to be used for any and all uses in humans (including all diagnostic, therapeutic and preventative uses). Under the MedPharm License Agreement, the Company is required to make future milestone and royalty payments to MedPharm. We are obligated to make aggregate milestone payments to MedPharm of up to GBP 1.150 million upon the achievement of specified development milestones (payable in Great British Pounds). Additional milestone payments are due upon the achievement of certain development and commercial milestones achieved outside the United States, payable on a country by country basis. Royalty payments must be paid to MedPharm in an amount equal to a single-digit percentage of net sales of all MedPharm Product sold by us during the royalty term in the territory. Royalties shall be payable, on a country-by-country basis, during the period of time commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on December 4, 2028. Each party has the right to terminate the agreement in its entirety upon written notice to the other party if such other party is in material breach of the agreement and has not cured such breach within ninety (90) days after notice from the terminating party indicating the nature of such breach.
Description of lipocure agreement									the LipoCure Agreement, the Company was required to pay an upfront fee upon signing of $150,000 and are required to make future milestone and royalty payments to LipoCure. The Company is obligated to make aggregate milestone payments of up to $19.8 million upon the achievement of specified development and commercial milestones. Royalty payments must be paid in an amount equal to a single digit to low double-digit percentage of annual net sales of royalty qualifying products, subject to certain adjustments. Royalties shall be payable during the period of time, on a country-by-country basis, commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on July 24, 2030.
Description of nanomerics collaboration agreement					the Company required to make royalty payments equal to a single digit percentage of annual net sales of royalty qualifying products. The Company is also required to make aggregate milestone payments of up to $103 million upon the achievement of specified development and commercial milestones, and sublicense fees for any sublicense relationships we enter into subsequent to the Nanomerics Collaboration Agreement. The Company’s obligation to pay royalties, on a country-by-country basis, shall commence on the date of first commercial sale of its licensed products and shall expire with respect to each separate licensed product, on the latest to occur of (a) the tenth (10th) anniversary of the first commercial sale of the first licensed product; (b) the expiration date of the last to expire of any valid claim (patent is set to expire on November 3, 2034); and, (c) the date upon which a generic product has been on the market for a period of no fewer than ninety (90) days. The Company has the right to terminate the agreement upon 180 days’ prior written notice to Nanomerics. Upon termination, the Company shall assign to Nanomerics all its right title and interest in all results other than results specific to (a) the Device (as defined in the Nanomerics Collaboration Agreement), its manufacture or use; and (b) the Technology, but excluding any clinical Results relating to the Compound or Licensed Products (all terms as defined in the Nanomerics Collaboration Agreement).
Description of nanomerics license agreement			the Company entered into a collaboration and license agreement with Nanomerics (the “Nanomerics License Agreement”) for the exclusive North American license to develop and commercialize a High-Density Molecular Masking Spray (MMS019) as an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans. Under the Nanomerics License Agreement, the Company is required to make royalty payments within a range of 5% to 15% of annual net sales of royalty qualifying products. The Company’s obligation to pay royalties, on a country-by-country basis, shall commence on the date of first commercial sale of its licensed products and shall expire with respect to each separate licensed product, on the latest to occur of (a) the tenth (10th) anniversary of the first commercial sale of the first licensed product; (b) the expiration date of the last to expire of any valid claim; and, (c) the date upon which a generic product has been on the market for a period of no fewer than ninety (90) days. The Company is also required to make aggregate milestone payments of up to $50 million upon the achievement of specified development and commercial milestones, and sublicense fees for any sublicense relationships we enter into subsequent to the Nanomerics License Agreement (any patent that issues from the currently filed provisional patent application would expire on August 24, 2041). The Company has the right to terminate the Nanomerics License Agreement upon 60 days’ prior written notice to Nanomerics. Upon termination, we shall assign to Nanomerics all its rights, title and interest in all of its results. Nanomerics has the right to terminate the agreement upon 60 days’ prior written notice if the Company has not secured funding by the Funding Expiry Date (as defined in the Nanomerics License Agreement). On December 31, 2020, the Company amended the Nanomerics License Agreement to extend the Funding Expiry Date to March 31, 2021.
Description of yissum research agreement		the Company entered into an Agreement for Rendering of Research Services with Yissum (the “October 2020 Yissum Research Agreement”) on substantially similar terms and conditions as detailed above in the May 2019 Yissum Research Agreement. Under the October 2020 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation of Liposomal Bupivacaine as well as efficacy and PK studies in animals. In consideration for the research services, the Company agreed to pay research service fees of $81,000 in six equal monthly installments. In connection with the completion of our initial public offering, we paid Yissum $40,500 towards the total consideration of $81,000. All services to be provided under the October 2020 Yissum Research Agreement will be completed by June 30, 2021.		the Company entered into an Agreement for Rendering of Research Services (the “May 2019 Yissum Research Agreement”), with Yissum. Under the May 2019 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation, preparation and characterization of Liposomal Bupivacaine for size zeta potential, drug loading and rate of drug release. In consideration for the research services, The Company agreed to pay research service fees of $81,000 in equal monthly installments. The Company retains ownership in all our intellectual property rights and any intellectual property belonging to either the Company or Yissum prior to the execution of the May 2019 Yissum Research Agreement will remain the sole property of either the Company or Yissum, respectively. All data generated from the provision of the May 2019 Yissum Research Agreement, including any reports, which are specifically required and contemplated under the May 2019 Yissum Research Agreement, shall be owned by the Company upon full payment of the research services fees. Each party will be entitled to terminate the agreement in the event of a breach by the other party of its obligations under the agreement, including, but not limited to, any payment failure, which is not remedied by the breaching party within 30 days of receipt of written notice from the non-breaching party. All services to be provided under the May 2019 Yissum Research Agreement will be completed by March 31, 2020.
Description of cooperative research and development agreement								the Company entered into a CRADA with NCATS. This collaboration is for the continued development of its product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain. The term of the CRADA is for a period of four years from the effective date of the agreement and can be terminated by both parties at any time by mutual written consent. In addition, either party may unilaterally terminate the CRADA at any time by providing written notice of at least sixty (60) days before the desired termination date. The agreement provides for studies that are focused on the pre-clinical characterization of NES100 as a novel analgesic for acute and chronic non-cancer pain, and for studies to further develop NES100 through IND enabling studies. There are certain development “Go/No Go” provisions within the agreement whereby, if certain events occur, or do not occur, NCATS may terminate the CRADA. These “No GO” provisions include: i) lack of efficacy in all animal pain models, ii) no reliable and sensitive bioanalytical method can be developed, iii) manufacturing failure due to inherent process scalability issues, iv) unacceptable toxicity or safety profile to enable clinical dosing, and v) inability to manufacture the NES100 dosage form.
Description of lipocure agreement.									the LipoCure Agreement, the Company was required to pay an upfront fee upon signing of $150,000 and is required to make future milestone and royalty payments to LipoCure. The Company is obligated to make aggregate milestone payments of up to $19.8 million upon the achievement of specified development and commercial milestones. Royalty payments must be paid in an amount equal to a single digit to low double-digit percentage of annual net sales of royalty qualifying products, subject to certain adjustments. Royalties shall be payable during the period of time, on a country-by-country basis, commencing on the first commercial sale and ending upon the expiration of the last-to-expire patent claim on the licensed product, which is set to expire on July 24, 2030.
Description of cooperative research and development agreement								The term of the CRADA is for a period of four years from May 6, 2020 (the effective date of the agreement) and can be terminated by both parties at any time by mutual written consent.
MedPharm License Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Milestone and royalty payments						$ 1,150,000
Nanomerics Collaboration Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Milestone and royalty payments			$ 50,000,000		$ 103,000,000
Nanomerics Collaboration Agreement [Member] | Minimum [Member]
Research and Development and License Agreements (Details) [Line Items]
Milestone and royalty payments percentage			5.00%
Nanomerics Collaboration Agreement [Member] | Maximum [Member]
Research and Development and License Agreements (Details) [Line Items]
Milestone and royalty payments percentage			15.00%
Yissum Research Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Description of yissum research agreement		the Company entered into an Agreement for Rendering of Research Services with Yissum (the “October 2020 Yissum Research Agreement”) on substantially similar terms and conditions as detailed above under the May 2019 Yissum Research Agreement. Under the October 2020 Yissum Research Agreement, the Company shall provide funding for research and development studies to be performed by researchers at Hebrew University related to the formulation of Liposomal Bupivacaine as well as efficacy and PK studies in animals. In consideration for the research services, the Company agreed to pay research service fees of $81,000 in six equal monthly installments. In connection with the completion of the Company’s IPO, the Company paid Yissum $40,500 towards the total consideration of $81,000. All services to be provided under the October 2020 Yissum Research Agreement were completed by June 30, 2021.
Research service fees				$ 81,000
Research and development in process							$ 337,500
Lipocure Research Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Research and development in process							$ 250,000
Lipocure Research Agreement [Member] | Subsequent Event [Member]
Research and Development and License Agreements (Details) [Line Items]
Research service fees	$ 200,000
Research and development in process	$ 400,000
Forecast [Member] | Lipocure Research Agreement [Member]
Research and Development and License Agreements (Details) [Line Items]
Research service fees paid in quarterly payments										$ 270,000

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - USD ($)	1 Months Ended
	Jul. 26, 2021	Feb. 16, 2021	Jan. 31, 2021
Subsequent Events [Line Items]
Net proceeds (in Dollars)		$ 16,000,000
Stock Options [Member]
Subsequent Events [Line Items]
Purchase shares of common stock	20,225
Exercise price per share (in Dollars per share)	$ 4.32
Expiration period, description	The Options granted to the directors will vest upon the one-year anniversary of the grant date, and have a ten-year expiration date.
Initial Public Offering [Member]
Subsequent Events [Line Items]
Initial public offering shares		1,800,000
Public offering price (in Dollars per share)		$ 10
Gross proceeds (in Dollars)		$ 18,000,000
Common stock shares authorized		100,000,000
Preferred stock shares authorized		10,000,000
Restricted stock awards vested		5,056
Stock based compensation (in Dollars)		$ 50,000
Description of notes payable			the Company issued notes with an aggregate principal amount of $75,000 and $25,000, respectively. These notes were issued to Anthony Mack, Chief Executive Officer and significant investor of the Company for $75,000 and Christopher Chipman, Chief Financial Officer, for $25,000. These notes were subsequently repaid with proceeds from the initial public offering in February 2021.
RRD Note amount (in Dollars)		$ 493,480

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of antidilutive due to the net loss - shares	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Stock Options [Member]
Equivalent common shares
Equivalent common shares	736,593	486,101	736,593	486,101	486,101	236,458
Warrants [Member]
Equivalent common shares
Equivalent common shares	95,056		95,056		5,056
RRD Note Conversion [Member]
Equivalent common shares
Equivalent common shares		43,909		43,909	49,897	26,746

Prepaid Expenses and Other Cu_6

Prepaid Expenses and Other Current Assets (Details) - Schedule of prepaid expenses and other current assets - USD ($)	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020		Dec. 31, 2019
Schedule of prepaid expenses and other current assets [Abstract]
Prepaid insurance	$ 703,316	$ 8,257		$ 3,328
Prepaid research and development	200,000
Legal retainer	3,050	3,643
Consulting fees	8,825	5,838
Other prepaid expenses and current assets	5,731	534		1,855
Total prepaid expenses and other current assets	$ 920,922	$ 18,273	[1]	$ 5,183
[1]	Derived from audited financial statements

Accounts Payable and Accrued _4

Accounts Payable and Accrued Liabilities (Details) - Schedule of accounts payable and accrued liabilities - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of accounts payable and accrued liabilities [Abstract]
Deferred CEO compensation	$ 1,073,075	$ 1,028,110	$ 680,400
Research and development expenses	69,605	1,045,503
Insurance premiums	448,789	2,874
Legal expenses	768,811	437,471
Professional fees	47,748	253,462	177,096
Interest payable/accrued	291,406	270,000	$ 138,762
Accounting consulting fees	6,235	45,904
Tax expenses	10,000	13,365
Other	64,197	19,235
Total accounts payable and accrued liabilities	$ 2,779,866	$ 3,115,924

Notes Payable (Details) - Sch_3

Notes Payable (Details) - Schedule of notes payables - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Related party notes payable
Related party notes payable, Beginning Balance	$ 1,000,000	$ 1,000,000	$ 500,000
Related party notes payable, Notes issued	100,000		500,000
Related party notes payable, Note Payments	(100,000)
Related party notes payable, Ending Balance	1,000,000	1,000,000	1,000,000
Notes payable, Beginning Balance	1,565,580	1,264,520	500,000
Notes payable, Notes issued	100,000	301,060	764,520
Notes payable, Note Payments	(593,480)
Notes payable, Ending Balance	1,072,100	1,565,580	1,264,520
Less: Current portion of notes payable, Beginning Balance	543,990
Less: Current portion of notes payable, Notes issued	100,000	279,470	764,520
Less: Current portion of notes payable, Note Payments	(593,480)
Less: Current portion of notes payable, Ending Balance	50,510	543,990
Total non-current portion of notes payable, Beginning Balance	1,021,590
Total non-current portion of notes payable, Notes issued		21,590
Total non-current portion of notes payable, Note Payments
Total non-current portion of notes payable, Ending Balance	1,021,590	1,021,590
Anthony Mack 2018 Promissory Note [Member]
Related party notes payable
Related party notes payable, Beginning Balance	500,000	500,000	500,000
Related party notes payable, Notes issued
Related party notes payable, Note Payments
Related party notes payable, Ending Balance	500,000	500,000	500,000
Anthony Mack 2019 Promissory Note [Member]
Related party notes payable
Related party notes payable, Beginning Balance	500,000	500,000
Related party notes payable, Notes issued			500,000
Related party notes payable, Note Payments
Related party notes payable, Ending Balance	500,000	500,000	500,000
Related Party Notes Payable [Member]
Related party notes payable
Related party notes payable, Beginning Balance
Related party notes payable, Notes issued	100,000
Related party notes payable, Note Payments	(100,000)
Related party notes payable, Ending Balance
RRD Note [Member]
Related party notes payable
Notes payable, Beginning Balance	493,480	264,520
Notes payable, Notes issued		228,960	264,520
Notes payable, Note Payments	(493,480)
Notes payable, Ending Balance		493,480	264,520
SBA PPP Loan [Member]
Related party notes payable
Notes payable, Beginning Balance	72,100
Notes payable, Notes issued		72,100
Notes payable, Note Payments
Notes payable, Ending Balance	$ 72,100	$ 72,100

Notes Payable (Details) - Sch_4

Notes Payable (Details) - Schedule of principal payments on note payables - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Schedule of principal payments on note payables [Abstract]
2021	$ 50,510	$ 543,990
2022	21,590	21,590
2023	1,000,000	1,000,000
Total payments	$ 1,072,100	$ 1,565,580

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of Black-Scholes option-pricing model	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Schedule of Black-Scholes option-pricing model [Abstract]
Expected term (years)	5 years 9 months 7 days	5 years 2 months 26 days	5 years 2 months 26 days	5 years 6 months 14 days
Risk-free interest rate	1.05%	0.49%	0.48%	2.03%
Expected volatility	79.40%	68.47%	68.50%	57.23%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%

Stock-Based Compensation (Det_5

Stock-Based Compensation (Details) - Schedule of stock option activity - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Schedule of stock option activity [Abstract]
Number of Shares, Beginning (in Shares)	486,101	236,458
Weighted- Average Exercise Price, Beginning	$ 9.89	$ 9.89
Weighted- Average Remaining Contractual Term (Years), Beginning		8 years 11 months 15 days	9 years 6 months 3 days
Aggregate Intrinsic Value, Beginning
Number of Shares, Ending (in Shares)	736,593	486,101	236,458
Weighted- Average Exercise Price, Ending	$ 8.10	$ 9.89	$ 9.89
Weighted- Average Remaining Contractual Term (Years), Ending	8 years 8 months 23 days	8 years 8 months 4 days
Aggregate Intrinsic Value, Ending
Number of Shares, Options exercisable (in Shares)	502,197
Weighted- Average Exercise Price Options exercisable	$ 9.58
Weighted- Average Remaining Contractual Term (Years), Options exercisable	8 years 3 months 7 days	8 years 1 month 24 days
Aggregate Intrinsic Value, Options exercisable
Number of Shares, Forfeited (in Shares)		(20,225)	(30,337)
Weighted- Average Exercise Price, Forfeited		$ 9.89	$ 9.89
Number of Shares, Cancelled (in Shares)			5,056
Weighted- Average Exercise Price, Cancelled			$ 9.89
Number of Shares, Granted (in Shares)	250,492	269,868	135,336
Weighted- Average Exercise Price, Granted	$ 4.62	$ 9.89	$ 9.89
Weighted- Average Remaining Contractual Term (Years), Granted
Aggregate Intrinsic Value, Granted